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Graft-versus-Host Disease 
Eosinophils, Chimerism and Clinical Features in Patients Undergoing 
Allogeneic Hematopoietic Stem Cell or Multivisceral Transplantation 
Julia Cromvik 
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine 
The Sahlgrenska Academy at University of Gothenburg 
Graft-versus-host disease (GVHD) is a potentially severe complication that may 
develop after allogeneic hematopoietic stem cell transplantation (HSCT). It can 
also occur after transplantation with isolated intestinal grafts or after 
multivisceral transplantation (MVTX). GVHD is difficult to diagnose. The aims 
of this thesis were to 1) investigate the potential of the eosinophilic granulocyte 
as an immunoregulatory cell and biomarker in GVHD, 2) determine the 
incidence, risk factors and clinical features of GVHD in MVTX, 3) evaluate the 
utility of lymphocyte chimerism analyses to predict overall survival and risk of 
GVHD after HSCT. In paper I, we used an in vitro model of GVHD to see if 
eosinophils could inhibit allogeneic T cell proliferation. In paper II, flow 
cytometry was used to examine patterns of surface receptors on blood 
eosinophils from transplanted patients +/- GVHD and +/- systemic 
glucocorticoids. Paper III is a retrospective epidemiological study of patients 
with acute GVHD after MVTX. In paper IV, the predictive capacity of 
chimerism analyses and impact of chimerism status on the duration of 
immunosuppression was evaluated. It was found that eosinophils can inhibit 
allogeneic T cell proliferation in vitro and that eosinophils in patients with acute 
and chronic GVHD have an activated phenotype, which is altered by systemic 
steroid therapy. Our conclusion is that the blood eosinophils are activated and 
have immunoregulatory capacity in GVHD, and might serve as a biomarker of 
GVHD. In MVTX, it was seen that a tumor diagnosis or neoadjuvant 
chemotherapy were possible risk factors for GVHD. Finally, chimerism analyses 
could not predict relapse, survival or GVHD after HSCT. However, patients 
with mixed chimerism or chronic GVHD had longer treatment time with 
cyclosporine A.  
Keywords: Graft-versus-host disease, eosinophilic granulocyte, intestinal 
transplantation, multivisceral transplantation, chimerism analysis ISBN:  978-91-628-
9824-3 (print), 978-91-628-9825-0 (PDF)  http://hdl.handle.net/2077/42336
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Den så kallade graft-versus-host sjukdomen (GVH) eller "transplantat mot värd-
sjukdomen" är en av de vanligaste komplikationerna efter transplantation med 
benmärg eller blodstamceller. Dessa transplantationer ges med syfte att bota 
svårbehandlade benmärgssjukdomar som akuta leukemier. Cirka hälften av de 
transplanterade får en akut eller kronisk form av GVH. Även vid 
transplantationer av andra organ som tunntarmstransplantation eller då 
tunntarmen transplanteras tillsammans med magsäck, tolvfingertarm, lever och 
bukspottskörtel (en så kallad multivisceral transplantation), finns en risk för 
GVH.  
GVH uppkommer då de transplanterade immuncellerna reagerar mot vävnad hos 
den transplanterade. Tidigare forskning har föreslagit att en vit blodkropp, den 
eosinofila granulocyten skulle kunna användas som en laboratoriemarkör för 
GVH. En laboratorieanalys som tas regelbundet efter stamcellstransplantationer 
är så kallade chimerismanalyser, vilket visar hur stor andel av patientens 
immunceller som kommer från den som donerat blodstamcellceller (givaren) 
respektive från patient själv.  
I denna avhandling undersöker vi GVH ur flera perspektiv. I delstudie I, används 
en laboratoriemodell av akut GVH för att se om eosinofiler kan hämma 
aktiverade T-celler. I delstudie II, har vi undersökt om eosinofiler i blodet hos 
transplanterade patienter har ett speciellt molekylmönster vilket skulle kunna 
utnyttjas vid diagnostik. Vi har studerat patienter med akut och kronisk GVH, 
samt med och utan kortisonbehandling. I delstudie III, har vi genom att studera 
patientjournaler undersökt förekomst, prognos och klinisk bild av patienter som 
drabbats av akut GVH efter multivisceral transplantation. I delstudie IV, 
studerade vi om läkaren genom chimerismanalys vid tre månaderskontrollen 
efter transplantation kunde förutsäga överlevnad, återfallsrisk, och utveckling av 
GVH, och om dessa faktorer påverkade hur länge patienten stod på 
immunhämmande behandling med cyklosporin A.  
Våra resultat visar att eosinofiler kan hämma aktiverade immunceller (T-celler) i 
en laboratoriemodell av GVH, samt att eosinofilerna uttrycker olika 
molekylmönster på sin yta vid akut och kronisk GVH. Detta kan indikera att 
blodeosinofilerna aktiveras vid GVH och möjligen kan hämma GVH-reaktionen. 
Vi såg också att en cancerdiagnos eller cytostatikabehandling före tarm- eller 
multivisceraltransplantation är en möjlig riskfaktor för att patienten ska drabbas 
av akut GVH. Chimerismstatus kunde inte förutsäga återfall, överlevnad eller 
förekomst av GVH efter blodstamcellstransplantation. Däremot hade patienter 
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med blandad chimerism och kronisk GVH längre behandlingstid med 
cyklosporin A. 
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Transplantation of allogeneic hematopoietic stem cells or bone marrow is a 
treatment option for patients with malignant diseases or bone marrow failure 
syndromes. The technique of allogeneic HSCT was first developed for patients 
with severe bone marrow failure syndromes, like aplastic anemia, and by help of 
cells from related donors.1 The discovery  of the immunosuppressive drug  
cyclosporine A2 made it possible to use bone marrow transplantations with 
unrelated donors. The transplantations became an established treatment during 
the 1970s.3 According to the World Health Organization,1 altogether more than 
one million bone marrow or stem cell transplantations have been done and 
approximately 50 000 are done per year worldwide.  
 ?Allogeneic? means that the patient receives cells from another individual, as 
opposed ??? ?autologous? stem cell transplantation, when the patient receives 
their own cells. The allogeneic transplant can consist of bone marrow cells 
harvested from the crista iliaca (hip bone) of the donor. Another option is 
peripheral blood stem cell transplantation.1 In this case, the donor has taken 
injections with granulocyte-colony-stimulating factor (G-CSF) to stimulate the 
hematopoietic stem cells (CD34+ cells) in the bone marrow, so they leave the 
marrow and enter the bloodstream. These cells are harvested by help of 
apheresis. In both cases, the patient then receives the harvested stem cells as an 
intravenous infusion.  
There are two mechanisms behind the use of allogeneic HSCT in malignant 
diseases. 1) firstly to give the patient an increased dose of chemotherapy in the 
so called conditioning therapy which can be either myeloablative (MAC), which 
means that it depletes the bone marrow irreversibly of hematopoietic stem cells, 
or reduced (RIC), where there is residual hematopoiesis. The use of 
transplantations with RIC (RICT) has made it possible to transplant older 
patients, up to 70 years of age, owing to reduced toxicity. 2) secondly to induce 
a so called graft-versus-leukemia (GVL) effect meaning that the new cells will 
recognize the tumor cells as foreign and suppress them in an immunological 
way. The GVL effect is a desirable effect, but it cannot be separated from the 
undesirable graft-versus-host reaction that may result in graft-versus-host-
disease (GVHD).  
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Transplantation of the isolated small bowel is used as a treatment option in 
patients with intestinal failure combined with life-threatening complications of 
total parental nutrition. Intestinal failure occurs when there is a reduced 
absorptive surface area in the small intestine. Among adults, it can occur after 
extensive surgical resections and in children as a consequence of congenital 
diseases.4 The definition of intestinal failure is "the reduction of gut functions 
below the minimum necessary for the absorption of macronutrients and/or water 
and electrolytes, such that intravenous supplementation is required to maintain 
health and/or growth".4 Unfortunately, long-term total parental nutrition is 
associated with risk of central venous catheter-related infections, occlusions, 
thrombosis and also increased risk of intestinal failure associated liver failure.5 
In patients with intestinal failure-associated liver disease or 
tumors/desmoids/neuroendocrine pancreatic tumors spreading to the mesenteric 
root, a multivisceral transplantation can be performed. In the classical 
multivisceral transplantation, all abdominal organs are completely eviscerated 
and then transplanted ?en bloc?: stomach, duodenum, pancreas, small intestine 
and liver. These operations are performed with some variations, for example the 
modified multivisceral, when the liver is not transplanted. Another alternative is 
that the spleen or kidney can be included in the transplant. The first intestinal 
transplantations were performed in the 1980s. The Intestinal Transplant Registry 
started to report data in 1985. According to this registry, 2887 intestinal 
transplants had been performed worldwide until February 2013.6 The registry 
includes both small intestine transplants, liver and intestinal transplants, 
modified multivisceral and multivisceral transplants. An illustration of the 
different grafts can be seen on the next page.  
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Figure 1. Isolated small bowel transplantation to the left and multivisceral transplantation 
including stomach, duodenum, liver, small intestine to the right.  The illustration is adapted 
and used after permission from Pécora RA, et al: Arq Bras Cir Dig.2013 Jul-Sep; 26(3):223-
9. 7 
 
 
????????????????????????? ????? ?????????? ?????? ???????? ?????????????? ??????s. 
The GVHD reaction depends on three components: 1. a graft containing 
immunologically competent cells, 2. a recipient, whose tissues express tissue 
antigens, not present in the donor 3. an immunosuppressed recipient, not capable 
to immediately eliminate the response of the transplanted cells. This was 
proposed 50 years ago by Billingham.8 Further research has confirmed that 
GVHD reactions occur when tissue (blood products, bone marrow or solid 
organs) containing T cells are transferred allogeneically, which means from one 
individual to another. Later studies in mice have shown that the immunological 
cells are T cells9 and that an increase in T lymphocytes in cell-depleted bone 
marrow transplant correlates with development of acute GVHD in humans.10 
The donor-derived T cells do not attack the graft as they are HLA-identical. 
Accordingly, intestinal GVHD cannot occur after intestinal transplantation.  
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The most common clinical situation with GVHD reaction is after allogeneic 
BMT or HSCT. According to the Ferrara model,
11
 the immunopathogenesis of 
acute GVHD consists of three phases. In phase 1, there is a tissue damage 
induced by the conditioning regimen. Especially the gastrointestinal tract is 
affected and intestinal permeability increases, causing endotoxins like 
lipopolysaccharide (LPS) to translocate the bloodstream, where it stimulates 
secretion of cytokines through Toll-like receptors. This leads to an activation of 
antigen presenting cells. This facilitates phase 2, in which donor T cells become 
activated and start to proliferate, stimulated by interleukin 2 (IL-2). In the final 
phase 3, the effector phase, both cellular effector cells like natural killer (NK) 
cells and cytotoxic T cells together with soluble inflammatory mediators like 
TNF-α, IFN-γ, IL-1 and NO all amplify each other. This “cytokine storm” may 
cause transient or permanent tissue damage, especially in the skin, 
gastrointestinal tract (GI tract) and liver, which are the most common affected 
organs in acute GVHD after HSCT. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunopathogenesis of acute GVHD. Abbreviations: LPS= lipopolysaccharide, 
APC=antigen presenting cell. 
However, these allogeneic T cells cannot alone explain why suppression of 
allogeneic T cells does not always cure GVHD. Another question is why only 
skin, GI tract and liver are affected in acute GVHD. Here some authors
12
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emphasize the role of the recipient tissue and propose that an impaired three-way 
crosstalk between immune cells, tissue homeostasis and the insults (resident 
microflora, toxins) lead to decreased immune responses and increased tissue 
damage, resulting in  development of GVHD in these tissues.  
The pathogenesis of chronic GVHD reactions is less known. Chronic GVHD is a 
heterogeneous multiorgan systemic disease, with similarities with 
rheumatological diseases like systemic sclerosis. There are indications that there 
are disturbances among donor B cells, donor T cells and probably also among 
other cells, like the eosinophilic granulocyte. One sign of a disturbed B-cell 
development is the occurrence of alloreactive autoantibodies, which are reactive 
with recipient cells. For example, male recipients with stem cell grafts from a 
female donor can develop antibodies against the Y-chromosome-encoded HY-
protein. These antibodies can precede chronic GVHD.
13
 In addition, 
autoantibodies directed against the PDGF receptor have been seen in extensive 
chronic GVHD and in patients with scleroderma. These autoantibodies have 
been proposed to be biologically active and stimulatory of collagen expression 
and reactive oxygen signaling.
14
 Perhaps they can increase fibrosis development 
in patients with chronic GVHD. However, the precise role of autoantibodies in 
chronic GVHD needs to be further specified.  
Donor T cells are thought to play a key role in chronic GVHD, since in vivo T 
cell depletion is a prophylactic measure that effectively prevents the 
development of acute and chronic GVHD.
15
 Thymic damage is also proposed to 
be a mechanism, as patients with extensive chronic GVHD display delayed 
immune recovery and production of naïve thymus-derived T cells, as assessed 
by measurement of T-cell receptor excision circle (TREC) contents.
16
  
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
. 
 
 
Figure 3. The pathophysiology of chronic graft-versus-host disease. Six features of chronic 
GVHD. a) thymic dysfunction due to conditioning regimen and in some cases also prior acute 
GVHD. b) decreased negative selection of T cells in thymus. c) immune deviation to Th2-type 
cytokine response, d) release of Th2 cytokines and release of fibrogenic cytokines like IL-2, IL-10 
and TGF-?? ????????????-derived growth factor (PDGF) released by macrophages. e) decreased 
numbers of regulatory T cells and f) B cell dysregulation and production of autoantibodies. 
Reproduced with permission from Nature Publishing Group. 17  
In conclusion, the pathogenesis of chronic GVHD is still poorly understood, but 
most probably it is a combination of defective immunological tolerance 
concerning both B and T cells, which results in autoantibody production, pro-
fibrotic pathways and a defective central tolerance due to thymic dysfunction.17 
 
GVHD has been well-known as a serious complication after HSCT since the 
first published studies from the Seattle group.18 Acute GVHD occurs in 
approximately 50%17 of the patients, after an allogeneic HSCT and is 
responsible for the majority of of transplant-related mortality in hematopoietic 
stem cell recipients.17 Chronic GVHD  occurs in approximately 50% of the 
patients surviving one year.19 A diagnosis of GVHD can cause a prolonged use 
of immunosuppression, permanent organ dysfunction, and increased risk of 
infections. 
GVHD is more uncommon in solid organ transplant recipients compared with 
allogeneic HSCT recipients However, the highest rates are seen among MVTX 
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recipients, where 12% incur acute GVHD compared to 4.6% among those with 
an isolated small bowel transplant.20 In contrast, the mortality due to GVHD 
after solid organ transplantation is very high, with mortality rates of 80-100%.21, 
22 
 
GVHD is traditionally divided into two variants, acute and chronic. According to 
the original Glucksberg-Seattle classification23 all types of GVHD that  occurred 
within 100 days after transplantation were classified as acute GVHD. Chronic 
GVHD was diagnosed as GVHD occurring after 100 days. Later research has 
revealed a more complex picture and the NIH consensus group24 have proposed 
the following categories:  
 Classic acute GVHD occurring within 100 days after 
transplantation. No diagnostic or distinctive features of chronic 
GVHD.  
 Persistent, recurrent and late onset of acute GVHD. Debut of 
symptoms > 100 days after transplantation. Can occur after 
withdrawal of immunosuppression or after donor lymphocyte 
infusions (DLI: s).  
 Classic chronic GVHD: Can occur at any time after 
transplantation.  
 Overlap syndrome: Can occur at any time after transplantation. 
Has a feature of both chronic GVHD and acute GVHD. 
Sometimes referred ??? ??? ??????? ??? ????????? ?????? ????
category in the NIH 2005 classification.25  
According to the existing classification from the NIH24, it is the clinical features 
of GVHD that determine whether it is an acute or  chronic form. Thus, after 
2005, diagnosis of GVHD is primarily based on clinical picture rather than on 
the temporal relationship to the transplantation, as originally defined in the 
Glucksberg-Seattle classification.23 The NIH consensus groups for diagnosis24 
and for histopathological disease26 recommend biopsies to confirm the diagnosis 
of GVHD in situations, where there are no diagnostic features and only 
distinctive clinical features of GVHD, for example nail loss or depigmentation. 
It is not compulsory if the patient has at least one diagnostic manifestation, for 
example lichen-planus in mouth or genitalia. Unfortunately, a biopsy can be hard 
to obtain (in some organs, especially if the patients have low platelet levels). 
Another problem is that the histopathological biopsies can be inconclusive due 
to inadequate tissue sampling or that immunosuppressive treatment was started 
before the biopsy was taken. 
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The NIH pathology working group has defined minimal histopathological 
criteria to classify active acute or chronic GVHD. They propose that organ-
specific criteria should be used, for example ductopenia and portal fibrosis in 
liver biopsies.26  Ductopenia means reduction in the number of intrahepatic bile 
ducts in the liver. There are also minimal criteria for acute/active GVHD like 
apoptosis in epidermal skin layer or variable apoptotic crypt in the GI tract.    
 
The acute forms of GVHD usually affect the skin, the liver or the intestine. In 
skin-GVHD the patient has an exanthema. In acute liver GVHD the patient has 
elevated liver enzymes, which in the worst case scenario can lead to manifest 
liver failure. The intestinal GVHD manifests as voluminous diarrheas and in 
severe cases also as melena. Here an intestinal biopsy by help of a colonoscopy 
or sigmoideoscopy27 is necessary to differentiate acute GVHD from intestinal 
CMV infection or other infectious causes of diarrheas. There also exists a form 
of acute GVHD in the upper gastrointestinal tract with symptoms of anorexia, 
dyspepsia, food intolerance, nausea and vomiting.28  
Several grading systems of acute GVHD are in use. The first grading of acute 
GVHD was the Glucksberg-Seattle classification23 from 1974 in which grading 
(grades I-IV) of skin, liver and GI tract were used together with performance 
status. This was revised some years later by Thomas et al,.29 A more recent 
grading classification is the International Bone Marrow Transplant Registry 
(IBMTR)30 grading system (grades A-D), in which the ????????? performance 
status is not included. In this grading, there is first an organ grading of skin, liver 
and GI tract depending on rash size, bilirubin levels and diarrhea volumes. These 
values together constitute the overall grade: 
 Grade A: there is only a stage 1 skin involvement 
(maculopapular rash over <25% of the body).  
 Grade B: stage 2 skin involvements together with stage 1 or 
2 gut or liver involvement. Stage 1-2 liver involvement 
occurs when total bilirubin is 34-??????????????????????-2 
gastrointestinal involvement is when volume of diarrhea is 
550-1500 ml/day.  
 Grade C: Stage 3 involvement of any organ system: 
(generalized erythroderma >50% of body area, elevated 
bilirubin 103-2??????????or diarrhea >1500mL/day).  
 Grade D: Stage 4 involvement of any organ (generalized 
erythroderma with bullous formation, total bilirubin>255 
?????/l, and severe pain and ileus. 
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Figure 4. Different manifestations of acute skin GVHD. A) disseminated maculopapular 
exanthema; b) perifollicular papular lesions; c, d) erythematousus rash of the c)  palms and 
d) soles; e) reticular erythema and f) purpura. Used with permission from John Wiley and 
Son.31 
 
 
The picture of chronic GVHD is complex as characterized by several clinical 
manifestations of  varying severity and clinical course. The disease can involve 
diverse organs including skin, nails, hair mouth and oral cavity, eyes, genital 
organs, GI tract and liver, lungs and the hematopoietic, neurologic and 
musculoskeletal systems. The clinical features are often similar to systemic 
rheumatological ????????????????????????????????????????????? syndrome, as many 
patients suffer from dryness of the eyes and mouth and sclerodermatous skin. 
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Figure 5. Similarities in clinical picture of oral chronic GVHD and oral lichen planus. 
Ulcerative and erythematosus lesions of the buccal mucosa in oral chronic GVHD (a) upper 
picture and in oral lichen planus (b) lower picture. Used with permission from John Wiley 
and Son. 32 
According to the latest classification of chronic GVHD, the NIH consensus 
group
24
 recommends that the diagnosis of chronic GVHD requires at least one 
diagnostic manifestation of chronic GVHD or at least one distinctive 
manifestation of chronic GVHD plus a pertinent biopsy, laboratory, or other test 
(e.g., pulmonary function test), evaluation by a specialist (ophthalmologist, 
gynecologist), or radiographic imaging showing chronic GVHD. In the same 
way as in acute GVHD, alternative diagnoses, e.g. nail dystrophy due to 
onychomycosis, Candida albicans infections of the mouth and drug reactions 
need to be excluded. An overview of diagnostic, distinctive and other features of 
chronic GVHD is given in Table I. The table is a simplified and adapted version 
from Table 1 in the NIH Consensus development on criteria for clinical trials in 
chronic GVHD, Jagasia et al, Biology of Blood and Marrow Transplantation 21 
(2015) 389-401.
24
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Table I. Signs and symptoms of chronic GVHD 
Organ or Site Diagnostic Distinctive¹ Other features ² Common ³ 
Skin Poikiloderma Depigmentation Sweat impairment Erythema 
 
Lichen-planus Papulosquamous Hypopigmentation Maculo- 
 
Sclerotic featues lesions Hyperpigmentation papular 
 
Morphea 
  
rash 
Nails 
 
Onycholysis, nail 
loss 
  Scalp and body 
hair 
 
Loss of body hair Thinning scalp 
 Mouth Lichen-planus Ulcers 
 
Erythema 
    
Gingivitis 
Eyes 
 
New onset dry, 
gritty Photophobia 
 
  
or painful eyes Periorbital 
 
   
hyperpigmentation 
 Genitalia Lichen-planus 
   
 
Lichen-sclerosis 
   GI tract Esophageal web 
 
Exocrine pancreas Nausea 
   
insufficiency Vomiting 
    
Diarrhea 
    
Weight loss 
Liver 
   
Bilirubin, 
    
ALP> 2 x 
    
upper limit 
    
of normal 
Lung Bronchiolotis Air trapping and Cryptogenic 
 
 
obliterans (BOS)⁴ bronchiectasis organizing 
 
  
on chest CT pneumonia 
 Mucles, fascia Fasciitis or joint Myositis Edema 
 
joints 
stifness or 
contrac- or polymyositis⁵ Muscle cramps 
 
 
tures due to 
fasciitis 
   
 
or sclerosis 
   Hematopoietic 
  
Thrombocytopenia 
 and immune 
  
Eosinophilia 
 
   
Autoantibodies 
 Other 
  
Pericardial and 
 
   
pleural effusions 
 ¹ In all cases, infection, drug effect, malignancy, or other causes must be excluded 
 ² Can be acknowledged as part of the chronic GVHD manifestations if diagnosis is confirmed 
³ Common refers to shared features by both acute and chronic GVHD 
 ⁴ BOS can be diagnostic for lung chronic GVHD only if distinctive sign or symptoms  are present 
also in another organ 
⁵ Diagnosis of chronic GVHD requires biopsy 
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???????????????????????????????????????????????????????????????????????????????
basis of a retrospective study from Seattle of twenty patients.18 In the present 
grading from the NIH consensus group24: the grading of chronic GVHD consists of 
a performance score according to Eastern Cooperative Oncology Group (ECOG) in 
addition to an organ scoring of eight organs: skin, mouth, eyes, GI tract, liver, lung, 
joints and fascias, and genital tract. Every organ is scored with respect to the 
presence of GVHD as either 0 (none) to 1 (mild), 2 (moderate) or score 3 (severe). 
In addition, other indicators should be mentioned like eosinophilia, 
thrombocytopenia, and ascites. It is recommended that eyes and female genitalia 
are scored by an ophthalmologist and gynecologist, respectively. The score from 
these eight organs are then used in order to calculate a global score of mild, 
moderate or severe chronic GVHD.  
 
The category of overlap GVHD was introduced by the NIH consensus group25 in 
2005 as a sub-category of chronic GVHD. According to that classification, patients 
with simultaneous features of both chronic and acute GVHD should be classified 
??????????????????????????????????????????????????????????????????????????
in clinical practice. Some studies have indicated that these patients have a worse 
prognosis compared to those with classical chronic GVHD.33,34 Several authors 
report it to be difficult to use the overlap classification in clinical practice35 and 
therefore the definitions have been clarified in the new NIH consensus document 
from 2014.24 In this document they recommend documentation of specific 
manifestations (acute and chronic), when scoring organ severity at debut and at any 
time of chronic GVHD with the purpose to achieve a more complete 
documentation of chronic GVHD syndrome and to facilitate retrospective 
??????????????????????????????diagnosis in patient with clinical chronic GVHD.  
 
There are no generally accepted diagnostic or therapeutic biomarkers in GVHD. 
Therefore NIH has established a biomarker working group. They have proposed 
three groups of biomarkers in chronic GVHD in their latest consensus document 
from 2015: a) diagnostic biomarkers, b) prognostic biomarkers, used to foretell the 
risk of developing chronic GVHD and c) predictive biomarkers to forecast the 
response to therapy.36 Most biomarkers hitherto identified belong to the group of 
diagnostic biomarkers. Eosinophilic counts were proposed as diagnostic biomarker 
in the first consensus document from 200637, but are no longer mentioned in the 
update from 201536. This could be due to a recent study from a Danish group. Their 
study could not find any association between eosinophilic counts and long-term 
outcome in patients with chronic GVHD.38 The NIH consensus group updated its 
consensus report in 201536, and concludes that much remains to be done before we 
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have validated consensus biomarkers for GVHD.  
During the last years, several research groups have launched candidate biomarkers, 
for example Levine et al.,39 who proposed an algorithm composed of the cytokine 
receptors: tumor necrosis factor receptor 1 (TNFR1) and ST2 together with 
regenerating isled-derived protein 3?????????, which is lectin secreted by Paneth 
cells in the intestinal mucosa. This algorithm could ameliorate prediction of non-
relapse mortality at six months and adjustment of immunosuppressive therapy. 
Others40 have proposed the cytokines: B cell activating factor, and the chemokine 
C-X-C motif chemokine ligand 10 (CXCL10) as predictive biomarkers in acute 
GVHD and BAFF, CXCL10 and C-X-C motif chemokine ligand 11 (CXCL 11) as 
diagnostic biomarkers in chronic GVHD. 
 
The recommended standard prophylaxis is the immunosuppressive calcineurin 
inhibitor, cyclosporine A (CsA) and a short course of the cytotoxic drug 
methotrexate. After transplantation CsA is recommended during six months in the 
absence of GVHD. The dose should not be tapered if there are signs of acute 
GVHD or signs of chronic GVHD exceeding mild skin disease.41 Another strategy 
is so called T cell depletion using polyclonal anti-thymocyte globulins. A recent 
meta-analysis has shown that ATG, significantly reduces the risk of severe acute 
GVHD (grade II-IV), but do not improve overall survival. The prevalence of 
chronic GVHD was not possible to evaluate in the meta-analysis.42 The doses and 
timing of ATG differ at different centers. At Sahlgrenska University Hospital, it is 
often used before transplantation with unrelated donors. During the last years, new 
protocols with high-dose of cyclophosphamide during one of the first days after 
transplantation have been developed.43 Cyclophosphamide can inhibit alloreactive 
T cells generated after a HLA-mismatched transplantation, for example after 
haploidentical HSCT,44 and leave the non-dividing hematopoietic stem cells 
unaffected.  
The first line therapy of acute GVHD is systemic glucocorticoids, such as 
prednisone given at 1-2 mg/kg. This regimen has been used during the last 
decades. Glucocorticoids are steroid hormones secreted from the adrenal cortex. 
They have physiological effects in normal life, as they control metabolism by 
stimulating gluconeogenesis in the liver and mobilize amino acids from extra-
hepatic tissues. Glucocorticoids also inhibit glucose uptake in muscles and adipose 
tissue and mediate the stress response.45 In clinical practice glucocorticoids are 
used as anti-inflammatory and immunosuppressive drugs. Most of the actions of 
the glucocorticoids are mediated through the intracellular glucocorticoid receptor 
(GR) in the cytoplasm. After activation, the receptor-steroid complex translocates 
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to the nucleus, where it binds to DNA and induces and represses the expression of 
target genes.
46
 This activation is called the genomic mechanism of the 
glucocorticoid receptor. The process is time-consuming and therefore accounts for 
a delayed onset of the clinical effect (6-8 hours) in clinical practice. 
Glucocorticoids also express more immediate reactions (within minutes), like 
cerebral effects as euphoria, apathy and depression. This action is mediated 
through non-genomic mechanisms of membrane-coupled receptors in the plasma 
membrane.
47
  
In eosinophilic diseases, glucocorticoids are an effective anti-inflammatory drug. 
This effect is due to an inhibition of the synthesis of the cytokines that prolong 
eosinophilic survival, like interleukin 3 (IL-3), IL-5 and granulocyte-macrophage 
colony stimulating factor (GM-CSF)
48
 and also an induction of  programmed cell 
death, so called apoptosis.
49
 There is also an inhibition of the release of mature 
eosinophils from the bone marrow and an increased destruction of eosinophils in 
the reticuloendothelial system after intake of glucocorticoids.
50
 Among physicians 
it is well known that glucocorticoids result in a rapid decrease in eosinophilic 
blood counts. There are two different pathways of apoptosis
51
: the extrinsic 
(receptor-mediated pathway) in which there is an activation of the “death”-
receptor, FAS/CD95 followed by formation of the death-inducing complex and 
caspase-8 activation. The other pathway is the intrinsic pathway (mitochondrion-
centered) pathway. This can be induced by DNA damage, oxidative stress or 
cytosolic Ca2
+
 overload. Apoptosis of human eosinophils can be induced by one of 
the pathways, for example Fas-mediated apoptosis
52
 or by help of both the intrinsic 
and extrinsic pathways.
53
  
For patients with limited chronic GVHD in the eyes, skin or genital areas, an 
alternative is local treatment for example topical glucocorticoids for skin and 
genital involvement and eye drops. Systemic immunosuppression should be 
considered in patients with chronic GVHD and a score of 2 or more in any single 
organ.
24
 An unanswered question is what treatment to choose when the 
glucocorticoids do not work, so called steroid resistant GVHD. In one study only 
55% of the patients with acute GVHD responded to systemic steroid therapy and 
35% achieved a durable complete remission.
54
 This is in congruence with earlier 
studies in which 44% obtained an overall complete or partial response.
55
 In 2012, 
the American Society of Blood and Marrow Transplantation (ASBMT) reviewed 
29 studies concerning GVHD therapy for steroid-refractory cases
56
 and concluded 
they could neither recommend any therapy before another, nor dissuade the use of 
any substance out of the following immunosuppressive therapies: mycophenolate 
mofetil, methotrexate, extra-corporeal photopheresis, daclizumab, alemtuzumab, 
horse ATG, and sirolimus.  
15 
 
There is a lack of therapeutic guidelines, but there exist a multitude of therapies 
which have been tested at different centers. For example, extra-corporeal 
photopheresis is supposed to eradicate T cells but the exact mechanism is 
unknown, and there is a lack of randomized clinical trials evaluating this method.57 
Another new alternative is ruxolitinib (Jakavi®), a JAK2-inhibitor supposed to 
inhibit inflammation in steroid resistant acute and chronic GVHD.58,59 Also cell 
therapies with regulatory cell types have been tried and are examined in clinical 
studies. The prospect is that these cells would down-regulate the allogeneic T cell 
activity in GVHD. Here bone-marrow derived mesenchymal stromal cells have 
been used in order to treat steroid-resistant acute GVHD, since a case-report in 
2004.60 In one phase I study of 40 patients, no acute toxicity was reported.61 A  
Swedish phase II study has also shown promising results.62 As the human placenta 
contains cells with similar capacities, decidual stromal cells have been analyzed in 
GVHD. They cells have shown to highly suppress allogeneic T cell proliferation in 
vitro63 and  to induce an overall response rate of 75% in eight patients with acute 
steroid resistant GVHD.64 Studies have also been performed in the preventive 
setting using regulatory T cells from umbilical cord blood, which have been 
tolerated in eleven patients and resulted in both lower incidence of acute GVHD on 
100 days and absence of chronic  GVHD.65  
 
Among solid organ transplanted patients, GVHD is a very rare disease, but among 
solid organ grafts it is most prevalent after multivisceral (MVTX:s) and isolated 
intestinal transplantations (ITX:s). An American study of 241 patients, showed an 
incidence of 12% after MVTX and 5% after ITX20, which is in congruence with 
6% of GVHD in another study of 250 ITX patients66 and 13% among MVTX 
patients.67 The incidence of GVHD after an isolated liver transplantation is 1%.68  
Patients with GVHD after solid-organ transplantation typically develop fever, skin 
rash or pancytopenia two to six weeks after transplantation.68 The most prevalent 
clinical symptom is skin rash, but also diarrheas can occur unless the patient do not 
have a small bowel graft, as GVHD can not occur in the graft.69  
Another immunological complication, which can occur after AB0 or Rhesus (Rh) 
mismatched solid-organ transplantation is passenger lymphocyte syndrome (PLS). 
Here donor B cells react with the ??????????? erythrocytes and start producing 
antibodies, causing alloimmune hemolysis. This phenomenon can be severe and 
occurs in 18% of transplantations witch AB0 incompatibility.70 However, the 
diagnostic process of GVHD and PLS is complicated as these symptoms also can 
occur due to hemophagocytosis or as drug reactions. The clinical picture is also 
different depending on different grafts, as GVHD by definition can not occur in 
transplanted organs, for example can a recipient of intestinal grafts not incur 
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intestinal GVHD. The prevalence of chronic GVHD seems to be very rare and 
there exist only few studies, most of them are single center studies or case reports 
about chronic GVHD in this population.71, 72  
Traditionally the same diagnostic criteria have been used for GVHD among solid 
organ transplanted patients as for patients after HSCT. However, the situation is 
different compared to after allogeneic HSCT, as the recipient after MVTX or ITX 
still have their own bone marrow and immune system. The GVHD after these 
transplantations is caused by T cells in the graft. Therefore grafts with extensive 
lymphoid tissue, for example MVTX are a known risk factor of GVHD compared 
to ITX grafts.20 A situation with persistence of donor cells (less than 1% of total 
leukocytes), so called microchimerism often occurs after solid-organ 
transplantation.73 Normally, these donor cells are eliminated by the recipient by 
help of their immune system and the patient recover chimerism with 100% 
recipient cells. This is the opposite compared to after allogeneic HSCT, in which 
the desirable state is 100% donor cells. Macrochimerism (more than 1% donor 
cells of total leukocytes) has been proposed to be useful in the diagnosis of GVHD 
after liver transplantation.74 However, a recent article reports that macrochimerism 
may occur without GVHD and that macrochimerism was more common after 
MVTX than after ITX.75 The diagnostic of GVHD after MVTX and ITX is 
therefore still complex and challenging. 
The mortality has been reported to be very high after solid organ transplantation 
with mortality rates of 80%21 up to 100%22 after liver transplantation. There is a 
lack of consensus guidelines about treatment and both increased 
immunosuppression with corticosteroids have been described21 no treatment when 
mild disease,76 and a complete withdrawal of immunosuppression.77   
 
Rejection. A rejection means that the remaining immune system of the transplanted 
patient recognizes the transplanted organ as foreign and rejects it, leading to graft 
failure. Chimerism analyses are often used for early diagnosis of rejection. (See  
chimerism analysis section). 
Relapse. Even if the purpose of allogeneic stem cell transplantation is to achieve 
cure or a long  remission, there is a risk of relapse of the underlying hematological 
disease. The relapse risk is dependent on the original diagnosis and the risk of 
relapse is more significant in patients with a malignant disorder than in those with 
a benign diagnosis.  
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Before the stem cell infusion, the patient receives a conditioning treatment 
consisting of chemotherapy, sometimes with the addition of radiotherapy. The 
main purposes are to eradicate the malignant cells and to prevent rejection, so the 
new allogeneic stem cells can establish themselves in the bone marrow. 
After infusion of the allogeneic hematopoietic stem cells, the cells actively cross 
the blood/bone marrow endothelium barrier and stay in the bone marrow by 
activation of adhesion interactions.78 This process is called homing and starts 
within hours after the transplantation. Other cells like human neutrophils and 
specialized T cells can also home to the bone marrow, but only CD34+/CD38- cells 
can establish in the endo-osteal niches and reach long-term repopulation.78 
After homing, the engraftment starts, i.e., the transplanted stem cells start to 
proliferate and to ???????????????????????????????????????Some stem cells remain as 
quiescent stem cells, other self-renew or become committed to progenitor cells in 
the myeloid or lymphoid lineage.79 In clinical practice, the peripheral blood cell 
levels are very low, so called cytopenia, during the engraftment process. After 
allogeneic HSCT, the time until neutrophil engraftment (to 0.5 * 10⁹ cells/L on two 
consecutive days) usually ranges from 14 to 28 days.80 During this time of severe 
cytopenia, the patient is at high risk of infections.  
After  engraftment, the establishment of the donor immune system in the recipient 
continues, a process that takes months to years to complete.81 The innate immune 
system recovers within weeks, for example the epithelial barriers, which often have 
been damaged by the conditioning regimens. The barrier function recovers quickly, 
but the protective secretions such as IgA and lysozyme can be chronically 
subnormal, especially in chronic GVHD.82 Although the neutrophil counts recover 
within weeks, their functional properties such as chemotaxis, phagocytosis, 
production of superoxide, and killing of bacteria takes months to recover.81 
Eosinophil engraftment appears to follow the same kinetics as neutrophils, re-
appearing in the blood within 1 month post-transplantation.83 
The reconstitution of the adaptive immune system takes longer time. During the 
first months, the dominating cells are post-thymic T cells expanding from 
transplanted T cells.84 These T cells originating from grafted T cells, can have both 
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antimicrobial and antileukemic effects and dangerous pro-GVHD effects. The 
number of T cells co infused with the marrow illustrates that the majority of T cells 
after BMT is regenerated through peripheral expansion and not through thymus.85, 
86 
The B cells only exist in very low number during the first months after 
transplantation. Antibodies of recipient origin can be found for years after the 
transplantation, as long-lived plasma cells resident in the bone marrow can be 
resistant to chemotherapy and radiotherapy.87 Both the engraftment and the 
immune reconstitution processes can be delayed due to infections, GVHD or 
systemic treatment with glucocorticoids. 
 
The eosinophilic granulocyte belongs to the granulocytes in the innate immune 
system. The production of blood cells (hematopoiesis) starts in the red bone 
marrow in adults. All cells of hematopoietic origin derive from the pluripotent 
hematopoietic stem cell, which is recognized by the surface marker combination 
CD34+CD38-.88 These cells are harvested and used in allogeneic HSCT. There are 
two parts of the hematopoiesis, the lymphoid progenitors, which develop into the 
lymphocytes (B, T and NK cells). There are also myeloid progenitors which 
develop into platelets, erythrocytes (red blood cells), monocytes, dendritic cells, 
and the granulocytes. The granulocytes are cells with granules in the cytoplasm. 
The most common granulocyte is the neutrophilic granulocyte, essential for the 
defense against bacterial and fungal infections. 
The eosinophilic granulocytes are recognized by their coarse granules that stain red 
with eosin and their lobulated nucleus. Therefore, the research on eosinophils was  
limited by methodological difficulties until the 1990s, when the development of 
??????????????????????????????????????????????????????????????????????????????
?????????????????????????? ?????????????????????????????????????.89, 90 
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Figure 6. The normal hematopoiesis in adults. The cells in color are the cells, 
which can be found in peripheral blood. The other cells are normally only 
found in the bone marrow, thymus or in the lymph nodes. The illustration of the 
cells is used with permission from DocCheck pictures. 
 
In healthy individuals, the eosinophil levels are normally 0,04 - 0,4 x 10⁹/L.91 
Approximately 4% of the population have eosinophilia.92 The cells are generated 
continuously from the bone marrow. They only remain in the bloodstream for 
hours until they enter the tissue. Their intravascular life span is thought to be 25 
hours compared to 10 hours for neutrophils.93 They are primary tissue-dwelling 
cells and can survive for several days in tissues94 and up to three months if 
activated.95 In healthy individuals in non-inflammatory conditions, eosinophil 
infiltration have been found in spleen, lymph nodes and thymus and both 
infiltration and degranulation have been found in the gastrointestinal tract.96  
Earlier studies have shown that eosinophils of varying similarity exist in both 
vertebrates and non-vertebrates like insects. They seem to have an evolutionary 
conserved role in the immune system, although this role still is unclear.97 However,  
unexpected eosinopenia in patients with normal leukocyte concentration is very 
rare. A study showed that less than one of 1000 patients had eosinopenia, and the 
natural
killer cell
(NK cell)
megakaryocyte
myeloid progenitor lymphoid progenitor
pluripotent
hematopoietic stem cell 
CD34+
platelets
erythrocyte myeloblast
eosinophil
small lymphocyte
T lymphocyteB lymphocytebasophil neutrophil
monocyte
Cromvik 2016
20 
 
majority of these patients were under treatment with glucocorticoids.
98
 There also 
exist observations indicating that true eosinophil deficiency is often associated with 
conditions of dysregulated immunity (thymoma or hypogammaglobulinemia), or in 
combination with deficiency of basophils or in association with allergic diseases 
like asthma or urticaria.
99
  
Human eosinophils can produce and secrete over 30 cytokines, including both Th2-
associated cytokines like IL-4, IL-13, and the Th1-associated cytokines IL-12 and 
IFN-γ, but also immunoregulatory cytokines such as the proinflammatory TNF-α 
and the immunosuppressive IL-10.
100
 Eosinophils from humans can degranulate 
through several mechanisms. The most common mechanism is so called 
“piecemeal degranulation”, which means that fractions of preformed cytokines 
and/or granule proteins are selectively secreted through a regular vesicular-based 
process “piece by piece”.101 Classical “exocytic degranulation” with fusions of 
granules to the plasma membrane and release of all granule contents is rare in vivo, 
except when eosinophils are on the surface of a helminthic parasite. Also 
“cytolysis”, which means deposition of clusters of free extracellular granules upon 
lysis of the cell can occur as a “degranulation” process.102 However, the piecemeal 
degranulation seems to be the most relevant mechanism of storage and secretion of 
granules contents during physiological conditions.
103, 104
 The presence of preformed 
granule proteins prior to secretion makes the eosinophils different from most other 
immune cells, such as lymphocytes. The secretion of the preformed eosinophil 
cytokines is a rapid and stimulus-specific process, and different stimuli results in 
differential secretion of cytokines.
100
 Together with the cytokines, eosinophils also 
contain four cationic proteins stored within their cytoplasmic granules, eosinophil 
peroxidase (EPO), major basic protein (MBP), eosinophil cationic protein (ECP) 
and eosinophil-derived neurotoxin (EDN), which all under certain conditions can 
induce tissue damage and dysfunction.
105
  
The eosinophils also express several receptors. Resting human eosinophils highly 
express cysteine-cysteine chemokine receptor-3 (CCR3), which is the main 
receptor of eotaxins 1-3.
106
 The eotaxins are chemoattractants inducing eosinophil 
recruitment into tissue sites.
107
 In addition, the chemoattractant receptor-
homologous molecule expressed on T-helper type 2 (CRTH2) is commonly 
expressed on human eosinophils.
108
 Prostaglandin D2 selectively induces 
chemotaxis in eosinophils via CRTH2.
109
 Further, sialic acid immunoglobulin-like 
lectin 8 (Siglec-8) is primarily expressed on eosinophils.
110
 Several surface 
receptor have been reported to be up-regulated on activated eosinophils, like 
CD69, intercellular adhesion molecule-1 (ICAM-1, CD54) and the IL-5 receptor 
and Fc receptors in asthma
111
 and CD25 in acute GVHD.
112
 Also purified human 
blood eosinophils can express several integrin heterodimers: CD49d
113
, CD11b,  
CD11a, CD11c, CD18
114
. Integrin receptors like CD11b can be up-regulated on 
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human eosinophils and then bind to vascular cell adhesion molecule-1 (VCAM) 
after culture with IL-5.114 The eosinophils with expression of CD18 can bind to 
ICAM-1, ICAM-2 and to endothelial cells in inflammatory disorders like, 
eosinophilic esophagitis.115 
 
Traditionally, the eosinophil has been connected to helminthic infections116 and 
allergic diseases as an effector cell, which can effect tissue destruction mediated by 
cytotoxic cationic granule proteins. However, more recent studies have challenged 
the perception of the eosinophils as tissue-destructive cells. For example, IL-5 
blocking monoclonal antibodies (mepolizumab) decrease eosinophil levels in 
patients with allergic asthma, but could not ameliorate the late asthmatic response 
or airway hyper responsiveness to histamine in patients.117 A similar result has 
????? ????? ????????????? ??????????? ???m eosinophilic esophagitis. In these patients, 
the IL-5 blocking antibody did decrease the number of tissue eosinophils in the 
esophagus, but without any convincing symptom relief.118  
Human eosinophils can also recognize and become activated by both Gram-
negative and Gram-positive bacteria. Escherichia coli is a strong eosinophilic 
activator and can induce chemotaxis, degranulation and respiratory burst in human 
eosinophils.119 Bacterial lipopolysaccharides (LPS) from Gram-negative bacteria 
can induce IL-5 or IFN-? primed eosinophils to release mitochondrial DNA in a 
catapult-like fashion.120 
The last decades of research have also given a more complex picture, proposing 
that the eosinophil may have immunoregulatory properties in health and disease.121 
For example studies have shown that eosinophils can regulate T cell subset 
selection by indoleamine 2,3-dioxygenase (IDO).122 These authors continued these 
studies and found eosinophils which expressed IDO in thymus from children. Both 
IL-5 and IL-15 were found in thymus supernatant. Also thymic IDO 
immunoreactivity was highest in the youngest children. This can be an indication 
that eosinophils might regulate Th2 responses in young children.123 Animal studies 
from mice have proposed that activated eosinophils in the thymus are active in 
negative selection of T cells.124  
Inspired by these results, in 2010, mouse eosinophil  researchers proposed a new 
paradigm and hypothesized that eosinophils are actually regulators of Local 
Immunity And/or Remodeling/Repair in both health and disease- the LIAR 
hypothesis.125 For example, they propose that eosinophils gather in tissues, where 
there is a co-existence of dying cells and a significant pool of proliferating cells 
and/or stem cell activation, for example in the bone marrow, in the gastrointestinal 
tract, in the thymus and in the uterine endometrium. They can also suppress 
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immune responses, for example in a Th1/Th17 environment by help of 
immunosuppression.122 This is in congruence with Swedish studies from the 1980s, 
which have shown that purified eosinophilic granule proteins can inhibit 
lymphocyte proliferation126 in vitro and that eosinophils can alter T cell responses 
toward T helper 2122 or amplify Th 1 and Th 2 types of cytokine secretion in 
vitro.127 In allergic inflammation, eosinophils also seem to be active in repair and 
tissue modeling. For example, co-culture of primary human dermal fibroblasts 
together with human eosinophils of atopic subjects resulted in increased transcript 
of procollagen.128 
Newer studies of mice have shown that eosinophils localize together with plasma 
cells in the bone marrow of mice. The role of the plasma cells is to produce 
antigen-specific antibodies. In vivo studies in mice indicate that eosinophils secrete 
cytokines, like the proliferating-inducing ligand and IL-6, which support the 
survival of the plasma cells in the bone marrow. If the eosinophils were depleted, 
the plasma cells died by apoptosis.129 Similar results have also been shown the gut 
of mice. Here eosinophils also co-localized with eosinophils in the intestinal 
lamina propria and were essential for the maintenance of IgA+ plasma cells. 
Eosinophil-deficient mice had a defective intestinal mucous shield and altered  
intestinal microbiota.130 Also malignant plasma cells seem to be supported by 
eosinophils. A study of human bone marrow biopsies from patients with multiple 
myeloma showed co-localization of eosinophils and plasma cells and confirmed 
that eosinophils promoted the growth of malignant plasma cells in vitro.131 
Eosinophils have also been connected to other malignancies, as they have been 
found to induce proliferation of Reed-???????????????? ????????????? ????????.132 
Later studies have proposed that tissue eosinophilia is a strong unfavorable 
??????????? ??????? ??? ????????? ????? ???? ????????? ???????? ?????????? ??? ??????????
lymphoma.133 
 
The Charcot Leyden Crystal protein (CLC) was discovered in 1853 by J.M 
Charcot134, who identified it in the spleen of a patient with leukemia and later also 
Leyden135 studied this protein. It is found extracellularly in a variety of tissues, 
body fluids and secretions with inflammatory infiltrates including eosinophils and 
basophils. The CLC-protein accounts for 10% of the cellular protein in mature 
human eosinophils.136 In undamaged mature eosinophils, CLC-protein is located in 
minor primary granule. In reactive or damaged eosinophils it is located in nuclei, 
cytoplasmic areas and in the extracellular matrix.137 The details about the secretion 
of the CLC protein are not known. The CLC protein has unique auto crystallizing 
properties and can form distinctive hexagonal bipyramidal crystals. It was 
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originally proposed that CLC-protein was synonymous with eosinophil 
lysophospholipase
138
, but this has now been questioned
139
. Further studies of the 
CLC-protein structure have found that its x-ray crystallographic structure
140
 and the 
gene structure
141
 are similar to the members of the galectin family. CLC-protein is 
therefore designated galectin-10. Also CD4
+
CD25
+
 Tregs express galectin-10, 
which seems to be responsible for their suppressive capacity.
142
 Therefore the 
eosinophil researcher Helene Rosenberg
143
 proposed in an editorial that human 
eosinophils, which are the cell in the body with the highest expression of galectin-
10/CLC perhaps also could inhibit the function and proliferation of CD4
+
 T cells. 
The role of galectin-10/CLC in diseases is still enigmatic. It has been proposed to 
be a diagnostic marker to measure esophageal inflammation in eosinophil 
esophagitis together with other eosinophil-derived proteins like MBP, EPX
144
 and 
elevated galectin-10/CLC on patients with asthma or bronchopulmonary 
infection.
145
 
 
 
 
 
 
 
 
 
 
Figure 7. Pictures of abnormal eosinophils and Charcot-Leyden Crystals 
(CLCs) associated with acute myeloid leukemia. A) Abnormal eosinophils, (B) 
extensive bone marrow necrosis with CLCs, (C) bipyramidal shaped CLC with 
abnormal eosinophils in the background, and (D) electron photomicrograph of 
CLC. Reproduced with permission from Elsevier.
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Many diseases are associated with elevated levels of blood eosinophils 
(eosinophilia). There are two different groups: 
 The hematological diseases (primary, clonal disorders) 
 The secondary or reactive diseases 
According to the World Health Organization (WHO)147, the first group consists of: 
myeloid and lymphoid neoplasm with eosinophilia and abnormalities of the 
platelet-derived growth factor receptor (PDGFRA, PDGFRB or PDGFR1), chronic 
eosinophilic leukemia not other specified (CEL, NOS) or WHO-defined myeloid 
neoplasm with associated eosinophilia, and idiopathic hypereosinophilic syndrome 
and lymphocyte-variant hypereosinophilia and idiopathic hypereosinophilic 
syndrome (HES), which is a diagnosis of exclusion. The recommended therapy 
according to WHO147 is glucocorticoids in HES and lymphocyte-variant 
hypereosinophilia and hydroxyurea or IFN-? in CEL, NOS and tyrosinkinase 
inhibitor, imatinib in PDGFRA/B rearranged disease. 
Before the diagnosis of a primary hematological disease, it is important to exclude 
a secondary (reactive) cause of eosinophilia. In developing countries, the most 
common reactive causes of eosinophilia are infections, especially tissue-invasive 
parasites.148 In the developed countries, the majority of eosinophilia cases in  
outpatient care are due to allergic diseases, like allergic asthma.149 Drug reactions 
may also give rise to secondary eosinophilia. Other possible causes of eosinophilia 
can be eosinophil-associated cutaneus and fibrotic diseases e.g. eosinophilic 
fasciitis150 or eosinophil-associated respiratory diseases e.g. idiopathic chronic 
eosinophilic pneumonia151 or allergic granulomatosis and angiitis [Churg-Strauss 
syndrome].152 Another disease with increasing incidence is eosinophilic 
esophagitis153 an antigen-driven chronic inflammatory disorder characterized by 
infiltration of eosinophilic granulocytes into the esophagus, which normally is 
totally devoid of eosinophils. 
 
Some other diseases have been associated with the eosinophil, for example: GVHD 
since the first report of  in patients from the Seattle group18 in 1980. They observed 
that blood eosinophilia preceded GVHD which also was reported later among 
eleven of 39 patients after busulfan and cyclophosphamide conditioning.154 Early 
studies in 25 patients in 1980 showed an elevation of immunoglobulin E (IgE) in 
transplanted patients simultaneously with the development of acute GVHD.155 
Several case-reports have associated eosinophils with GVHD: for example 
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activated tissue eosinophils in a conjunctival biopsy in a patient with chronic 
GVHD
156
, and acute eosinophilic pneumonia after a debut of acute GVHD
157,158
 
and in association with chronic GVHD
159
 or severe eosinophilia concomitant with 
acute GVHD after donor lymphocyte infusion.
160
 Also eosinophilic fasciitis has 
been connected to chronic GVHD.
161
 A French case-report describes 
hypereosinophilia in two patients before debut of acute GVHD.
162
 There also exists 
a case-report indicating a possible association between GVHD and eosinophils 
after solid organ transplantation.
163
 One case-report describes a cutaneous 
eosinophilic infiltrate in a patient with lichenoid skin GVHD after liver 
transplantation.
163
 
There are also more extensive studies than case-reports about eosinophils and 
GVHD. In an American study, eight of ten children with hypereosinophilia had or 
developed chronic GVHD.
164
 Other report that eosinophilia is connected with a 
special features of chronic GVHD like sclerotic GVHD.
165
 Also levels of 
eosinophil cationic protein (ECP) on day +28 after transplantation have been 
connected with concurrent acute GVHD in children.
166
 However, there also exist 
other eosinophilic disorders after allogeneic HSCT, without occurrence of GVHD. 
For example in one case-report of eosinophilic folliculitis.
167
 Some authors also 
report that the presence of tissue eosinophil is not a reliable indicator of 
histological differential diagnosis of GVHD, as tissue eosinophils often exist also 
in drug-induced dermatitis.
168
 
Later studies have given contradictory results concerning the meaning of elevated 
eosinophil counts: The NIH biomarker consensus group proposed the eosinophil as 
a cellular marker of chronic GVHD in their article from 2005
37
, but the eosinophil 
is not included in their newer report from 2015.
36
 Studies have indicated that blood 
eosinophilia could be used as a negative prognostic factor
169
 or as a marker for a 
less-severe course of acute GVHD or chronic GVHD and even indicate improved 
overall survival.
170-173
 Another study found a high prevalence of eosinophilia (44%) 
at diagnosis of chronic GVHD, but no association with overall survival, relapse-
incidence or non-relapse mortality.
174
  
The most detailed study ever about eosinophilic counts in blood samples in patients 
with chronic GVHD is written by Mortensen
38
 in 2014 and their retrospective 
analysis of blood eosinophilia in 142 allogeneic stem cell transplanted patients. 
Their analysis showed no connection between concomitant blood eosinophilia and 
the appearance of chronic GVHD. They reported a significant decrease of blood 
eosinophil counts after start of systemic glucocorticoid treatment. There was no 
difference in prognosis between patients with or without eosinophilia with regard 
to GVHD. 
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There are very few studies about the phenotypic or functional properties of the 
eosinophil in GVHD. One study of eosinophils from peripheral blood from patients 
with acute GVHD, detected the IL-2 receptor subunit CD25 receptor on the surface 
of the eosinophils in almost all patients with acute GVHD112. An extensive 
prospective study from France did histopathological analyses of intestinal biopsies 
in all patients with suspected upper gastrointestinal GVHD.175 All 36 patients with 
confirmed histological digestive GVHD had tissue eosinophilia, in other words,  
eosinophils were only present when there were histological signs of GVHD, and 
eosinophil counts correlated with GVHD severity. In addition, 
immunohistochemical studies showed the presence of IL-5 and eotaxin in the 
tissue and electron micrographs showed many degranulated eosinophils in the 
tissue. This can be an indication that the tissue eosinophils were activated in the 
patients with GVHD in the upper gastrointestinal tract.  
 
 
????????????????????????????????????tate in an organism, when there are cells (not 
germ cells) from two or more lineages at the same time. Chimera is a word from 
the Greek mythology, describing a creature with the strength and body parts of 
many animals. Chimerism analysis is used to determine the genotypic origin of the 
hematopoiesis after allogeneic transplantations and determines the proportion of 
lymphocytes (or other subsets of cells) that derive from the donor and recipient 
respectively. It is necessary to obtain genetic markers from the donor and the 
recipient before the transplantation. Chimerism analyses are used to monitor  
engraftment kinetics after allogeneic HSCT. The analyses determine the 
proportions of lymphocytes (or other cells) that derive from the donor and 
recipient, respectively. There are different states of chimerism:176 
After allogeneic HSCT: 
 Complete chimerism: no recipient cells can be detected the in 
patient (the exact definition depends on the chimerism analysis 
method). Suggesting complete hematopoietic replacement after 
allogeneic HSCT.  
 Mixed chimerism: recipient T cells are detected, in particular cells 
like lymphocytes. 5-90% donor cells set the criteria.  
 Split chimerism: one or more lineages are of recipient-origin and 
one or more lineages are of donor-origin, e.g. e myeloid cells are 
100% from the recipient and 100% of T cells are from the donor . 
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After solid organ transplantation:  
 Macrochimerism: more than 1% donor cells are detected.  
 Microchimerism: less than 1% donor cells are detected. Normally 
found after solid organ transplantation.  
Traditionally patients who receive a MAC reach complete donor chimerism, as the 
engraftment process is faster. Repeated chimerism analyses are optional after 
standard MAC using conventional GVHD prophylaxis, as the majority will have a 
complete donor chimerism, according to the guidelines of the International Bone 
Marrow Transplant Registry177 Newer studies178,179 have verified that chimerism 
surveillance after MAC is of very limited clinical value as only 5% had <95% 
donor derived T cells in bone marrow at two to six months after transplantation.178 
On the other hand, among patients who received RICT, it is very common with 
mixed chimerism status. For example 43% in one study had a mixed chimerism 
<90% donor T cells on day 30 after transplantation.180 Therefore, chimerism 
analyses at 1,3,6 and 12 months are recommended after RICT during the first year 
in order to detect GVHD, graft loss or relapse early and because interventions such 
as donor lymphocyte infusions may depend on chimerism status.177 
If the chimerism analyses show mixed chimerism, it can signal threatening relapse 
or rejection. Proposed interventions are to decrease the immune suppression or to 
perform donor lymphocyte infusions (DLI). At the moment, there are no clear 
guidelines about these interventions and no national guidelines regarding the care 
about allogeneic HSCT recipients in Sweden. 
After solid organ transplantation, the interpretation of the chimerism analyses is 
different. Microchimerism <1% donor cells is known to occur in the immediate 
post-operative period and it can perhaps facilitate graft acceptance181, but the the 
existence of macrochimerism >1% donor cells in peripheral blood, bone marrow or 
other organs may precede threatening rejection.75 Macrochimerism >1% donor T 
cells can also occur after intestinal or multivisceral transplantation without signs of 
GVHD.75 
There are no international guidelines about the frequency of chimerism sampling 
after neither ITX or MVTX nor clear recommendations how to proceed when 
macrochimerism and/or GVHD is suspected. The recommendations concerning 
GVHD treatment are diverging and both increased immunosuppression21 or a 
complete withdrawal of immunosuppression77 have been proposed. 
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Immunosuppression is essential due to two reasons after allogeneic HSCT. The 
first reason is to prevent activation of the immune cells in the graft and 
consequently ????? ?????????? ???? ???????????? ??????? ???? thereby induce a GVHD 
reaction. ????????????????????????????????????????????????????????????????? it will 
not recognize the hematopoietic stem cells as foreign and start a rejection process 
followed by graft failure. The standard immunosuppression after transplantation 
consists of an induction phase directly after transplantation and a consolidation 
phase. Most often methotrexate (MTX) is given 3-4 times during the first week 
after transplantation together with cyclosporine A, CsA, a calcineurin inhibitor, 
which diminishes the capacity of T cells to divide. The concentration of CsA is 
measured weekly during follow up during the first months post transplant. 
Alternative treatments to CsA are tacrolimus (Prograf®), mycophenolate mofetil 
(Cellcept®), sirolimus (Rapamune®) or cyclophosphamide.182 No routine 
glucocorticoid treatment is given unless the patient develops GVHD or other 
complications. The immune suppressive therapy is normally tapered after the 
transplantation and if no complications occur, it can be discontinued after six 
months if the patient has achieved complete donor engraftment. 
The situation after solid organ transplantation is different, as the largest threat is 
graft rejection (acute cellular rejection or chronic rejection) and not GVHD. 
Another difference is that the recipient maintains their own immune systems, as 
they do not change hematopoietic stem cells. Therefore the immune cells, will 
constantly recognize the graft as foreign and the patients will therefore need 
lifelong immunosuppression. Otherwise, threatening graft rejection can occur at 
any time after transplantation. Among solid organ transplants, recipients of 
intestinal or multivisceral grafts need the most intensive immune suppression 
therapy, probably due to the volume of immune cells in the grafts. At Sahlgrenska 
University hospital, the standard protocol currently used  is the protocol from 
Pittsburg.183 It consists of two major principles, 1) recipient preconditioning with a 
single-dose of antithymocyte globulin induction therapy in combination with 
minimization of post transplant maintenance immunosuppression, 2) elimination of 
glucocorticoids that earlier had been a part of the maintenance 
immunosuppression. Later studies in mice have proposed that high doses of 
glucocorticoids and calcineurin inhibitors (like tacrolimus or CsA can cause potent 
Th1 suppression and thereby promote a Th2 deviation, which can increase the risk 
of chronic rejection.184 
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The main focus of this thesis was to better understand the incidence, prevalence, 
risk factors and pathogenesis of GVHD in patients after an allogeneic HSCT or 
intestinal transplantation (ITX) or multivisceral transplantation (MVTX). 
Concerning the pathogenesis, we have been especially interested in the role of the 
eosinophilic granulocyte and its interaction with T cells. 
The thesis is based on  the following hypotheses: 
 Eosinophilic granulocytes from healthy individuals can decrease 
allogeneic T cell proliferation in an in vitro-model of GVHD 
 Eosinophils from allogeneic transplanted patients have an 
increased capability to inhibit T cell proliferation compared to 
eosinophils from healthy persons 
 The eosinophils of HSCT patients with GVHD have a different 
phenotype compared to eosinophils from transplanted patients 
without GVHD 
 The surface receptors of the eosinophils are different in patients 
with acute and chronic GVHD 
 Eosinophils are activated in patients with GVHD 
 Treatment with systemic glucocorticoid treatment changes the 
phenotype of the eosinophil 
 Patients receiving MVTX have a higher risk of acquiring GVHD 
compared to patients with intestinal transplants 
 A tumor diagnosis and neoadjuvant chemotherapy are risk factor 
of GVHD after multivisceral transplantation 
 Chimerism status on day 100 after allogeneic HSCT can predict 
overall survival, disease-free survival and  development of chronic 
GVHD 
 Patients with mixed chimerism status have shorter duration of 
cyclosporine A therapy because clinicians will be prone to 
withdraw immunosuppression 
To test this, the thesis has the following specific aims: 
 By using functional tests to see whether eosinophilic granulocytes 
can decrease allogeneic T cell proliferation in an in vitro-model of 
GVHD (a so called mixed-lymphocyte reaction). Further studies 
of possible T cell suppressive mechanisms used by eosinophils, 
such as the requirement for cell-cell contact, IDO, galectin-10, 
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and IL-10.  
 To see if eosinophils from patients with chronic GVHD can 
inhibit T cell proliferation 
 Perform flow cytometry analysis of eosinophilic surface receptor 
in eosinophils from HSCT recipients with and without GVHD. 
 To use multivariate analysis for comparison of the patterns of 
surface receptors in HSCT recipients with and without acute 
GVHD, chronic GVHD and with and without systemic 
glucocorticoid treatment, respectively. 
 To do a retrospective clinical study and determine the  incidence 
of GVHD, as well as clinical features, risk factors, response and 
choice of therapy in  patients after ITX and MVTX.  
 By using survival analyses to determine whether chimerism status 
in allogeneic HSCT patients after RICT could predict overall 
survival, disease-free survival, non-relapse mortality and relapse 
incidence and using Cox regression to determine if the time with 
CsA was different among subgroups and F????????? ?????? ????? ???
see if incidence of acute GVHD was different among T cell 
chimerism groups (complete versus mixed). 
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In this chapter, more general considerations are discussed. Detailed descriptions of 
the methods used are found in the published studies and manuscript. 
 
In study I, 50 healthy study persons were recruited to donate peripheral blood for 
in vitro-assays of eosinophilic T cell regulatory function. Persons with ongoing 
glucocorticoid treatment were not included. The majority of these persons were 
recruited from students and employees from the research laboratories. As a 
consequence of the recruitment, there were more women among the healthy study 
persons and they also had a younger age, than the patients. The study was 
complemented with blood from eleven allogeneic HSCT recipients. Among these 
eleven patients, five had chronic GVHD and six did not have chronic GVHD. All 
patients were recruited from the Bone Marrow transplantation Unit, Sahlgrenska 
University Hospital. Unfortunately, we could not include patients with suspected 
acute GVHD, because of practical reasons and difficulties to include them before 
systemic glucocorticoid treatment had begun. All participants gave written 
informed consent.  
In study II, altogether 35 adult allogeneic HSCT patients were recruited from the 
Bone Marrow Transplantation Unit, at Sahlgrenska University Hospital after 
written informed consent. These patients were followed clinically and donated 
altogether 78 blood samples on different occasions, when they visited the out-
patient clinic. They were divided into groups depending on GVHD status and 
whether they were under systemic glucocorticoid treatment or not. 
In study III, consecutive intestinal or multivisceral patients, of all ages, who were 
transplanted at the Transplant Unit, Sahlgrenska University Hospital from January 
1, 1998 to December 31, 2014 were included retrospectively. This cohort included 
26 patients. No exclusion criteria were used.  
In study IV, all adult patients who received an allogeneic hematopoietic stem cell 
transplant with reduced intensity conditioning at Sahlgrenska University Hospital 
between January 1, 2005 and December 31, 2014 were investigated in retrospect. 
A total of 105 patients with a hematologic malignancy and who had undergone 
RICT, and with available blood chimerism data on day 100, and whom had not 
suffered from a relapse before day 100 were included. Those with a benign 
diagnosis were excluded as the risk of relapse is lower in this population, and they 
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usually receive other protocols of immunosuppression. Patients who received 
myeloablative conditioning were not included, as they normally do not develop a 
mixed chimerism. Other exclusion criteria were cord blood, haploidentical, or 
syngeneic transplantation as the chimerism is impossible or more difficult to 
interpret in such cases. Patients not in remission before transplantation were also 
excluded. 
 
The eosinophils were purified from heparinized blood within three hours after 
venipuncture. The erythrocytes were removed by help of 20 minutes of dextran 
sedimentation (dextran: blood=1:1) at room temperature. After the dextran 
sedimentation, differential gradient centrifugation at 400 g for 20 minutes at 4°C 
on a Ficoll gradient was used to separate mononuclear from polynuclear cells. The 
Buffy coat with mononuclear cells was removed. The granulocytes and remaining 
erythrocytes were found in pellet. Hypotonic lysis was used to remove the 
erythrocytes from the granulocytes. The hypotonic lysis was done in 3-4 cycles; by 
help of 6 ml distilled water for 35-40 seconds, followed by addition of 2 ml of 
3.4% NaCl in order to stop the reaction and achieve isotonicity. The granulocytes 
was washed in 15 ml Ca²+-???????????? ??????? ???????? ?????? ?????????????? ??
mM KCL, 1.7 mM KH2PO4, 8.3 mM Na2HPO4, 10 mM glucose, 1.5 mM MgCl2; 
pH 7.3). Next, eosinophils were separated from neutrophils by help of negative 
immune depletion as follows: All granulocytes were incubated together with 
magnetic beads coated with mAbs (MACS; Miltenyi Biotec Inc., Bergisch 
Gladbach, Germany) directed against CD3 (T cells), CD14 (monocytes), CD16 
(neutrophils), and CD19 (B cells). As eosinophils lack these receptors, they could 
pass the magnetic cell sorter VarioMACS, CS-column (MACS; Miltenyi Biotec), 
while the other cells were stuck in the magnetic column. Finally the eosinophils 
were washed twice in KRG. As a control of purity of the eosinophils, 200 cells 
were counted in a light microscope after cytospin (Cytospin; Shandon Scientific 
Co. Ltd., London, UK) and staining with Diff-Quick (Dade Behring AG, Deerfield, 
IL, USA). The purity was routinely ?98%.  
 
Healthy volunteers donated blood from which the PBMC responder cells were 
isolated. Pooled PBMC from 11 healthy volunteers were gamma-irradiated (25Gy; 
60Co source) and used as trigger cells. The concept is that the non-irradiated 
responder cells (T cells) respond to foreign tissue antigens (HLA) expressed by the 
mixture of PBMC from 11 non-related donors. This method has been adapted from 
the method used at the Clinical Immunology Laboratory, Sahlgrenska University 
Hospital. The purpose of the gamma-irradiation is to inhibit proliferation, so only 
the responder cells are able to proliferate, a so called one-sided MLR. Freshly 
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purified eosinophils were added either on the same day as the start of the MLR or 
two days later. After incubation for 6 days at 37°C, a low-dose beta-emitter 3H-
thymidine (1μ Curie/well: Perkin Elmer, Waltham, MA, USA) was added for 6 
hours and the cells were harvested using a cell harvester. A beta-scintillation 
counter (1450 Micro Beta TriLux; Perkin Elmer) was used to measure the 
incorporation of radioactive thymidine as a measure of cellular proliferation, which 
was expressed as counts per minute (cpm). To examine if cell-cell contact was 
necessary for the inhibiting effect, transwell-96 culture plates were used. In these, 
eosinophils were either cultured in permissive transwell inserts (3?m) or in non- 
permissive (0.4 ??? ones. The MLR culture was cultured in the receiver plate. The 
cell medium used in all MLR: s was RPMI 1640 supplemented with 10% human 
AB serum, 2 mM L-??????????? ??? ?????? ??????????? ???? ????? ??? ?-
mercaptoethanol.  
 
The purpose of the chimerism analyses is to detect the percentage of donor CD3+ 
cells (T lymphocytes), CD19+ (B lymphocytes) or hematopoietic stem cells 
(CD34+ ) or other hematopoietic cells in peripheral blood or bone marrow of the 
??????????????????????????????????????????????????????????????????????????????????????
strictly donor-derived (complete chimerism) or a mixture of donor-derived and the 
p??????????????????????????????????????????????????????????????????????????????????
the routine surveillance after bone marrow transplantation, but it is only done on 
demand after solid-organ transplantation. A prerequisite for the method to be 
performed is that pre-transplantation blood samples from the recipient and donor 
are available as references. These assays have been performed at the Department of 
Clinical Genetics, Sahlgrenska University Hospital as follows: Separation of 
mononuclear cells in to two fractions: non T cells and T cells by help of 
immunomagnetic beads (Dynabeads CD3 from Thermo Fisher Scientific). In some 
cases, CD34+ cells from the bone marrow were analyzed in addition using 
Dynabeads CD34. For fragment analysis, DNA was extracted from the isolated 
cells, followed by PCR amplification of short tandem repeats (STRs) with 
fluorescent tagging. STRs (sometimes called microsatellites) are short highly 
polymorphic DNA sequences repeated in tandem multiple times. After PCR 
amplification, the fluorescently labeled PCR-products were separated and detected 
by capillary electrophoresis on a Genetic analyzer 3500 or 3500xL (Applied 
Biosystems, CA, USA). The relative amounts of donor and recipient cells were 
calculated after genotyping, using the GeneMapper software (Applied Biosystems, 
CA, USA). This method was used when the donor and recipient have the same sex. 
In case of sex mismatch, a FISH-based method was used to score hybridization 
signals using chromosome X and Y specific DNA probes on interphase nuclei. At 
least 500 nuclei were included in the latter analysis. The FISH assay can 
occasionally be more sensitive than STRs, in sex mismatched cases. The reason is 
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that it directly measures the frequency of the minor component marker.185 
 
In studies I and II, flow cytometry of surface receptors on eosinophils was done 
using 3-color or 4-color flow cytometry. A FACSCanto IITM Flow Cytometer (BD 
Biosciences, Franklin lakes, NJ, USA) with Diva 6 software was used in all 
analyzes of the expression of surface markers. Flow Jo software (Tree Star Inc., 
Ashland, OR, USA) was used to analyze the results.  
In study I, T cells present in the eosinophil: MLR co-cultures were stained to 
determine if eosinophils preferentially suppressed the proliferation of CD4+ T 
cells, CD8+ T cells or regulatory T cells. The cells were incubated for 30 minutes 
at 4°C with CD4-APC-H7, CD8-FITC or CD8-PerCP-Cy5.5, CD25-APC or 
CD25PE, and CD127-Alexa Fluor 647 or CD127-FITC. Intracellular staining of 
the T cells was done after fixation and permeabilization with a Foxp3 
Fixation/Permeabilization kit (eBioscience, San Diego, CA, USA). Proliferation 
was monitored by intracellular staining for the proliferation marker Ki-67. 
Regulatory T cells were gated as CD4+, CD25+ and CD127 low/neg. Fluorescence 
Minus One (FMO)186 technique was used as a control of background staining. All 
data about surface receptors are expressed as median fluorescence intensity 
(median-FI).  
In study II, the analyses were done on whole blood (non-fractionated leukocytes) 
to avoid non-intentional activation of the eosinophils by the purification process.  
All flow cytometry analyses were done within 24 hours after venipuncture as we 
have shown that eosinophils alter their expression of surface markers if the cells 
are delays in the analyses. EDTA-anticoagulated blood was used and the 
erythrocytes were removed by repeated hypotonic lysis. Unfractioned leukocytes 
were incubated at 4°C for 15 minutes in the dark with a panel of fluorochrome-
conjugated mouse monoclonal antibodies directed against surface receptors. The 
gating strategy was to first set a granulocyte gate and then to gate for eosinophils 
based on high side scatter and low/no expression of CD16, to differentiate them 
from neutrophils.  
 
In study I, real-time quantitative PCR was used. First eosinophils were isolated as 
described under purification of eosinophils. Then RNA was extracted using the 
Rneasy Mini Kit (Qiagen, Valencia, CA, USA) and RNA quality and concentration 
were evaluated in the Experion Automated Electrophoresis System (Bio-Rad 
Laboratories, Berkeley, CA, USA). Total RNA was used to synthesize cDNA by  
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AMV reverse transcriptase, PCR-dNTP mix, RNAse inhibitor and random primer 
pd(N)6, (all from Roche Applied Bioscience, Mannheim, Germany). The protocol 
for cDNA synthesis was; 5 minutes at 20°C, 50 minutes at 42°C, 5 minutes at 70°C 
and a final step at 4°C.  
Eosinophilic expression of the genes for galectin-10 and hypoxanthine 
phosphoribosyltransferease were analyzed by Taqman gene expression assays 
(Applied Biosystems, Foster City, CA, USA) using  7500 real-time PCR system 
and 7500 System SDS software (Applied Biosystems). Eosinophils from healthy 
individuals were used as controls. We used the Pfaffl method algorithm187 to 
calculate the transcript levels of galectin-10 relative to those of the housekeeping 
gene hypoxanthine phosphoriboyltransferase.  
 
Study III and study IV included studies of the medical records. In study III, we 
created a table for each transplanted patient and collected clinical data such as 
protocol of immunosuppression, histopathological biopsy results and the 
?????????????????????????????????????????????????????????????????????????????????????
project about the follow-up of patients after ITX or MVTX. Study IV about 
chimerism analyses also included studies of the medical records. We used our local 
part of the EBMT registry to identify patients who fulfilled the inclusion criteria. 
Both studies have been approved by the Regional Ethics Committee in 
Gothenburg.  
 
 
In study I, paired Wilcoxon signed-rank test and Mann-Whitney U-test were used 
to test for statistical significance between groups. In study II, the Mann-Whitney 
U-test was used to analyze variables derived from the multivariate analyses with 
VIP-????????????? ??????????? ???????? ???? ????????????????? ???????? ?????????????????
used to detect differences between groups. All these analysis were done using 
GraphPad prism software (GraphPad, San Diego, CA, USA). In study IV, logistic 
regression was used to evaluate the impact of chimerism status on development of 
?????????????????????????????????????????????????????????????????????????????
whether duration of cyclosporine A therapy differed among groups. Logistic 
??????????? ?????????? ????????????? ???????????? ????? ??????????????????? ??? ?????
Institute, Cary, NC, USA. A p-value <0.05 was considered to be statistically 
significant in all studies.  
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In study II, we used multivaria??? ????????? ??? ???????? ???????????? ????????????
Partial Least Squares-????????????? ?????????? ?????-???? ???? ???????????-
?????????????????????????????????????????????????????????????????????????????????
statistical package (Umetrics, Umeå, Sweden). OPLS-DA is ?? ????? ??? ?????????
?????????? ????? ??? ????? ??? ?????????? ????????? ??? ?????? ????? ?????? ???? ???????????
between the more traditional partial component analyses (PCA) is that this method 
allows one to determine if the data set can discriminate between different study 
groups by help of Y-variables.188 For example, in study II, the method was used to 
see if the data set of eosinophilic surface receptors (X-variables) could discriminate 
transplanted patients with acute GVHD from those without GVHD; patients with 
acute GVHD were set as Y=1 and patients without GVHD were set as Y=2 and the 
median FI expression levels of different eosinophilic receptors were set as X-
variables. The OPLS-DA could then find differences and similarities between these 
two groups. 
Before the analysis by help of the SIMCA transformation tool, all X-variables were 
normalized by log-transformation, mean-centering and unit variance scaling. The 
purpose is to give every variable an equal chance of influencing the model. After 
calculation, a valid model might be generated. The quality of the model is defined 
by R2Y, a measure of the amount of variance in Y that is explained by the X-
variables. The R2Y-value therefore indicates to what extent that the X-variables 
can or cannot explain the differences between the studied groups. Internal 
validation of the models has been done using cross-validation, in which one of 
seven samples is removed and the analysis is done without that sample. When all 
objects have been removed once, the cross-validation will calculate a Q2Y value. 
A high value indicates that the model will give the same results even if one or 
many samples are removed. In univariate analyses, a p-level is used as a 
significance level. In OPLS-DA this is not possible, but instead permutation tests 
?????????????????????????????????????????????????????????????????????????????????????
overfit model occurs when there are few samples and many variables and the 
model is correct for the actual data, but will not be transferable or adequate in other 
populations. 
 
In study IV, we followed the EBMT statistical guidelines189 to choose patient-
related outcomes. For the survival analyses, when only two outcomes were 
possible, e.g. disease-free survival (DFS) and overall survival (OS), when the 
patient could be alive (event=0, censor) or dead (relevant event=1), Kaplan-Meier 
analysis was done.190 These analyses were done in SPSS Statistics 21. A log-rank 
test was used to see if there were significant differences between groups. When we 
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analyzed acute GVHD, we used the same variant of Kaplan-Meier analysis and 
log-rank test, because we only had two possible outcomes: acute GVHD=1 
(relevant event) and no acute GVHD (censored event= 0) . We did not have any 
competing events, as patients who had died during the first 100 days were 
excluded.  
Concerning non-relapse mortality (NRM) or relapse incidence (RI), the Fine and 
Gray’s method191 for competing risks was used. The reason for this was that there 
were three possible outcomes, exemplified by relapse incidence: event= 1, 
censored= 0 and death from non-relapse cause= 2. This analysis was performed 
using the software R, (http://www.r-project.org/), the package “cmprsk” and the 
CumIncidence function.
192
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The first study is based on the hypothesis that the eosinophilic granulocytes from 
peripheral blood can be T cell immunoregulatory in patients after allogeneic 
HSCT. It consists of functional studies of the eosinophilic granulocytes after 
isolation from peripheral blood. We used an in vitro model of GVHD, the mixed 
lymphocyte reaction, and co cultured eosinophils with proliferating T cells. 
We started with studies of eosinophils from healthy persons and we could see that 
eosinophils could suppress allogeneic T cell proliferation. This effect was only 
seen when eosinophils were added 1:1 to PBMC and it seemed to be specific for 
eosinophils, as neutrophils did not have this effect. (Figure 1A). The suppressive 
effect was also a feature of eosinophils from patients after HSCT (Figure 1C and 
D), but there was not any significant difference in suppressive capacity between 
eosinophils derived from the transplanted patients with GVHD compared to those 
without GVHD. 
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Figure 1. T cell proliferation measured as counts per minute in MLR/eosinophil co cultures with 
eosinophils from  healthy persons (A,B) or  HSCT transplant recipients with chronic GVHD (C, 
n=7) or no GVHD (D, n=6). MLR/neutrophil co cultures were used as controls (A). The ratio of 
eosinophils (or neutrophils) to peripheral blood mononuclear cells (PBMC) in the co cultures is 
indicated below the x-axis (A). Reproduced with permission from Elsevier. 
We continued to see if cell-cell contact between eosinophils and T cells was 
compulsory for the T cell regulatory effect of eosinophils. To test this, we cultured 
the eosinophils in transwell inserts. These inserts had permeable pores, enabling 
eosinophils to reach the T cells or non-permeable inserts where eosinophils would 
only be able to influence the T cells through cytokines or other soluble mediators. 
As seen in Figure 2, the suppression only occurred in the cell culture plates with 
permeable inserts. Our conclusion is that cell-cell contact is compulsory. 
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Figure 2. Contribution of cell-cell contacts on the inhibitory effect of eosinophils on allogeneic 
T cell proliferation. (n= 8 peripheral blood blood eosinophil donors in each group). Each data 
point represents the median counts per minute value of 3-4 replicate cultures derived from one 
individual. Reproduced with permission from Elsevier.  
We also tried to examine by which mechanisms the eosinophil practiced their 
suppression. Antibodies were used to block various molecules to try to diminish 
the inhibitory capacity of eosinophils. We could not identify the inhibitory 
mechanism, but in our hands, the eosinophilic granule proteins ECP, EDN, 
regulatory cytokine IL-10 and its receptor CD210, did not seem to be inhibitory 
mediators, as addition of the corresponding to the MLR did not diminish the 
inhibition. We also excluded the enzyme indoleamine 2,3-dioxygenase (IDO), as 
we could not measure signs of IDO-activity in the supernatants from the MLR.  
IDO is an enzyme, which can act immunosuppressive and inhibit T cell 
proliferation by metabolizing the essential amino acid tryptophan into 
kynurenine.
193
 An interesting finding was that RT-PCR analysis showed that 
eosinophils from allogeneic HSCT recipients expressed very elevated levels of 
galectin-10 mRNA, compared to healthy individuals, see Figure 3. However, the 
addition of antibodies to galectin-10 did not abolish or diminish the suppressive 
effect of eosinophils to a statistically significant degree, median inhibition before 
addition of antibodies to galectin-10 was 70% and after addition 47%.  
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Figure 3. Expression levels of mRNA for galectin-10 in eosinophils from peripheral blood from 
healthy control persons and in eosinophils from allogeneic hematopoietic  stem cell transplanted 
patients with and without chronic GVHD. Shown are the transcript levels of galectin-10 as 
determined by the Pfaffl method. For all patient eosinophils, each data point represents the mean 
of duplicate PCR reactions. Reproduced with permission from Elsevier.  
 
In study II, our aim was to examine the hypothesis that blood eosinophils are 
activated in GVHD. To do this, we analyzed blood eosinophil counts and 
percentage of leukocytes together with 15 surface markers on eosinophils by help 
of flow cytometry performed on 78 blood samples from 35 HSCT recipients. As 
we hoped to identify different patterns of receptors on the eosinophils, we used 
multivariate statistical methods to analyze the data. 
First, we could see that the eosinophils in the blood of patients with chronic GVHD 
had a different phenotype compared to the eosinophils from patients without 
chronic GVHD. It may be seen in Figure 5a that the majority of chronic GVHD 
patients (dark square) form a cluster above the horizontal line, whereas the 
majority of the patients without GVHD (indicated by open triangles) cluster below 
the line. This segregation is based on eosinophilic expression of surface markers. A 
column loading plot was done, of the eosinophilic receptors, see Figure 5b. The 
plots show that eosinophils from patients with chronic GVHD had relatively higher 
levels of surface receptors. Univariate analysis showed higher levels of CD11c, 
CD69, CD9 and CD18.  
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Figure 5. The pattern of surface receptors in eosinophils from peripheral blood samples from 
transplanted patients with chronic GVHD (cGVHD) differs from those of transplanted patients 
without GVHD (NoGVHD). A) OPLS-DA score plot based on flow cytometry analysis in patients 
with cGVHD (n=9; sampled on 14 occasions) and transplanted patients without GVHD (n=9; 
sampled on 15 occasions). Only variable with VIP-values>1.0 are included in the model. The y-
axis indicated the degree of separation of the study groups, and the x-axis indicates the arbitrary 
order in which the samples were entered into the model. B) Column loading plot of  the 
eosinophilic variables. Only parameters with VIP-values>1.0 are included. X variables that 
project in the same direction as the “cGVHD” column are positively associated with cGVHD, 
and inversely related to the “NoGVHD” column, which projects in the opposite direction. 
Reproduced with permission from John Wiley and Sons. 
After the chronic GVHD versus no GVHD comparisons, we next compared acute 
GVHD versus no GVHD. Here we could see that eosinophil markers could help to 
differentiate these two patient categories, and moreover, that the percentage of 
blood eosinophils (eos%) and the activation markers CD69 were the most 
important factors for this differentiation. 
Next, we examined if there was a stereotypical kind of activation of the eosinophils 
in GVHD or if they had different patterns of surface markers in acute and chronic 
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GVHD. A new OPLS-DA analysis could conclude that there were different 
molecular patterns in the groups of patients with acute and chronic GVHD, 
respectively. The markers CD18, CD11c, CRTH2 and CD9 were the molecules 
that differed most between the two types of GVHD, and were relatively more 
elevated in chronic GVHD than in acute GVHD. 
Systemic corticosteroids are the cornerstone of treatment of more severe forms of 
acute as well of chronic GVHD. Our next aim was to examine how glucocorticoid 
therapy affected the activated eosinophil phenotype displayed by patients with 
GVHD. As controls, we also investigated transplanted patients treated with 
systemic steroids for other causes than GVHD. In patients with GVHD, the results 
were striking: after systemic introduction of steroids several molecules, notably  
CD11c, CRTH2, CD44, CD9, CD18 and CD49d were all significantly down-
regulated. 
 
 
 
 
 
 
 
 
 
Figure 6. Systemic therapy of corticosteroids results in a down-regulation of surface markers in 
patients with chronic GVHD (n=12, sampled on 17 occasions) compared to eosinophils in 
patients with untreated chronic GVHD (n=9; sampled on 14 occasions). Univariate Mann-
Whitney statistical analyses . Data are shown as boxed with median horizontal lines and 
min/max whiskers. **P<0.01, ***P<0.001,**** P<0.0001. Reproduced with permission from 
John Wiley and Sons. 
We also compared the pattern of eosinophilic receptors from patients with chronic 
GVHD under glucocorticoid treatment with transplanted patients under 
glucocorticoid treatment, without a diagnosis of GVHD. The OPLS-DA analysis 
revealed that they had different phenotypes, as seen in Figure 7. 
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Figure 7. Eosinophils in blood samples from patients with chronic GVHD under systemic 
glucocorticoid therapy (cGVHD+ steroids) have a different phenotype compared to steroid-
transplanted patients without GVHD (NoGVHD+steroids). OPLS-DA score plot based on flow 
cytometry analysis of eosinophils in blood samples from patients with treated cGVHD (n=12; 
sampled on 17 occasions) and patients without GVHD under systemic glucocorticoid treatment 
(n=8, sampled on 14 occasions). Only variables with VIP-values >1.0 are included in the model. 
Reproduced with permission from John Wiley and Sons. 
 
The third study is a clinical retrospective study of the incidence of acute GVHD 
and possible risk factors for GVHD in a cohort of intestinal and multivisceral 
organ transplanted patients in Scandinavia. We also wanted to study the clinical 
features of GVHD and outcome of treatment strategy. We chose to examine the 
impact of the following parameters on the risk of GVHD: graft type (intestinal or 
multivisceral), malignancy as a cause of transplantation, chemotherapy or 
radiotherapy as neoadjuvant therapy, and inclusion of the spleen in the graft 
combined with recipient splenectomy. All 26 patients transplanted at Sahlgrenska 
University Hospital from January 1 1998 until December 31 2014 were 
investigated. 
Here we could see that 5/26 (19%) patients developed acute GVHD. No one 
????????????????????????????????????????????????????????????????????????????????
possible risk factor (P=0.001) as well as neoadjuvant chemotherapy/radiotherapy 
(P=0.004). However, graft type or a spleen-containing graft was not risk factors. 
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The clinical features included skin rash in four patients and hemolysis in the fifth 
patient (passenger lymphocyte syndrome). The diagnosis of acute skin GVHD was 
supported by the finding of macrochimerism (a maximum of 70% donor T cells in 
blood) in all four patients when they presented with the skin rash. The diagnosis of 
GVHD was difficult in most cases, especially as acute GVHD occurred at the same 
time as kidney failure, septicemia, acute rejection, pleural effusions and secondary 
hemophagocytosis in different patients. A complicating factor was that chimerism 
analysis was not always indicative, illustrated by one patient who had 
macrochimerism (27% donor T cell chimerism) without a diagnosis of GVHD. It 
was also difficult to choose the level of immunosuppression, as one patient 
incurred acute GVHD, acute rejection and EBV-driven PTLD at the same time. 
The treatment strategy also varied, such that immunosuppression was increased in 
4/5 (80%) patients when GVHD was confirmed, but in one case it was decreased 
following recommendations by the consultant hematologist who wanted to 
strengthen the patient’s own immune system in the fight against acute GVHD. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Donor T cell chimerism in four patients with acute GVHD.  D indicates the post-
transplantation day. The level of donor T cell chimerism is expressed as a percentage of donor-
derived cells of total CD3+ cells in peripheral blood. The different patients (Pat) are marked by 
their different number. Reproduced with permission from Elsevier. 
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In study IV, we wanted to see if chimerism status on day 100 after allogeneic 
HSCT can predict overall survival, disease-free survival and GVHD. We also 
focused on how clinicians interpreted chimerism data 100 days after 
transplantation, and to what extent and in what direction the laboratory data 
??????????? ???? ???????????? ??????? ??? ??????? ????????????? ??????? ??? ????????? ???
overall survival and disease-free survival in patients with mixed chimerism on day 
100 (?95% donor T cells) was shorter than in patients with complete chimerism. 
Here we could not see any significant difference between the groups. 
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Figure 9. Kaplan-Meier analysis of overall survival (OS) among patients (n=105) with complete 
(n=52) and mixed chimerism respectively (n=53) 100 days after transplantation. Log-rank test, 
p=0.77. The survival curve is terminated when less than five patients are at risk in each group. 
We also examined how biopsy-verified acute GVHD during the first three months 
was associated with chimerism status on day 100. There were more patients with 
mixed chimerism who incurred acute GVHD (n=15), than with complete 
chimerism (n=9), but the difference was not significant, p=0.22. 
The next step was to see whether the clinician was guided by chimerism status at 
day 100 in choice of treatment, especially if they withdrew the immunosuppression 
or prescribed donor lymphocyte infusions (DLI:s). Here we did a Cox regression 
analysis and found that patients with complete chimerism had shorter duration of 
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cyclosporine A therapy (hazard ratio 1.86, p=0.01), see Figure 10. The patients 
with chronic GVHD had a longer treatment time with CsA (hazard ratio=0.43, 
p<0.01). Bone marrow cells as donor source, a related donor or a diagnosis of 
acute GVHD were not associated with a significant longer or shorter time of CsA 
treatment. Patients with a related donor, had significantly more chronic GVHD 
compared to those with an unrelated donor, p=0.02.  
 
 
 
 
 
 
 
 
 
 
Figure 10. Days with cyclosporine A among patients with complete (n=52) or mixed (n=53) 
chimerism status at three months. Y-???????????????????????????????????????????????????????????
???????????????????????? ???????????????????????????????????????????????????????????
analysis, complete chimerism, hazard ratio 1.86, confidence interval: 1.19-2.93, p-value =0.01. 
The curve is terminated when less than five patients are at risk in each chimerism group.  
During the first 100 days, the immunosuppression was completely withdrawn in 
5/105 (4.8%) patients because of suspected relapse. Four of these patients 
subsequently developed mixed chimerism and one developed complete chimerism 
on day 100 after transplantation. Altogether, 14/105 patients (13%) received one or 
several donor lymphocyte infusions (DLI:s), eight of these were due to relapse 
(therapeutic DLI), and six were due to mixed chimerism (preemptive DLI). Here 
2/8 (25%) with relapse survived compared with 5/6 (83%) in the group with 
preemptive DLI ??????????????????????????????????????????????????????????????????????
exact test).  
In summary, our results indicate  that chimerism status on day 100 could not 
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predict overall survival, disease-free survival, relapse incidence, or non-relapse 
mortality. Patients with mixed chimerism and a diagnosis of chronic GVHD had 
longer time with CsA. We also found that the clinicians were influenced by 
chimerism results in their choice of immunosuppression such that CsA therapy was 
stopped in several patients with suspected relapse during the first 100 days, or 
preemptive DLI were given due to worrying mixed chimerism status. 
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The focus of this thesis is on GVHD after allogeneic HSCT, ITX or MVTX. We 
chose to study the role of the eosinophilic granulocyte, as it has been proposed to 
be a biomarker in chronic GVHD37 and to have immunoregulatory properties.100, 127 
In the first two articles, we focused on the role of the eosinophilic granulocyte in 
GVHD. Our first hypothesis was that the eosinophils could be immunoregulatory. 
Therefore, we focused on functional in vitro studies. In study I we saw that the 
eosinophils could inhibit allogeneic T cells proliferation, unlike the neutrophilic 
granulocytes. Our second hypothesis was that blood eosinophils would have 
different patterns of surface receptors in acute and chronic GVHD because the 
immunopathogenesis is different in these diseases, and possibly, the function of the 
eosinophil might differ in these two conditions. In study II, we found that patients 
with acute GVHD had higher levels of blood eosinophils and that there was a 
pattern of up-regulation of CD9, CD11c, CD18, CD69 on eosinophils from  
patients with chronic GVHD compared to transplanted patients without chronic 
GVHD. Both CD11c and CD18 belong to the leukocyte integrin subfamily, which 
mediates important cell-cell and cell-extracellular matrix interactions.114 Our 
interpretation is that eosinophils can act immunoregulatory in GVHD (study I) and 
that they have different phenotype in acute and chronic GVHD(study II). Probably 
this up-regulation of eosinophilic receptors facilitates for the eosinophil to bind to 
activated endothelial receptors like ICAM-1 and VCAM-1 and then enter the 
tissues, where it inhibits the GVHD reaction. Supporting data behind this is that 
eosinophil counts in our study (paper 2) were higher in patients with acute GVHD 
and also other studies have shown eosinophilia to be a presenting sign before acute 
GVHD.160,162 In contrast, a recent study could not find any association between 
hypereosinophilia and GVHD.38 
However, the unique and interesting finding in our study was that we not only 
examined the eosinophilic counts, but also evaluated the eosinophilic phenotypes 
(study 2) and functional properties (study 1). Among the very few studies of 
surface markers in human blood eosinophils in transplanted patients there is one 
article, which indicates that CD25 was up-regulated in patients with untreated 
treated acute GVHD.112 In common with us, they saw an effect of systemic steroid 
therapy, as CD25 was down-regulated on the surface of eosinophils after start of 
systemic steroid therapy.112 The most striking result was the global down-
regulation of eosinophilic surface molecules after start of systemic steroid therapy. 
The decrease in blood eosinophilic counts that we documented was also seen in the 
article by Mortensen38 and it was expected, as it is well-known that systemic 
corticosteroids give rise to eosinopenia by inhibition of IL-3-, GM-CSF- and IFN-
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γ-mediated eosinophil survival48 and by induction of apoptosis of the eosinophils.49 
By help of multivariate analysis we also could see that the esoinophils from 
patients with and without chronic GVHD differed with regard to their patterns of 
surface receptors. To our knowledge this has not been examined in GVHD before, 
but it is in agreement with recent studies that the eosinophils have different 
phenotypes in patients with eosinophilic esophagitis, inflammatory bowel disease, 
airway allergy
115,194
, systemic sclerosis
195
 and other diseases with eosinophil 
involvement. Our interpretation is that the eosinophils can adapt to different 
microenvironment such as in acute and chronic GVHD, respectively, two complex 
conditions with partly different immunopathogenetic background. Possibly, the 
eosinophils have a function in GVHD. These different molecular patterns could 
perhaps be exploited as a diagnostic aid in GVHD. It is an attractive option to 
identify blood-based biomarkers for the diagnosis of GVHD. In addition, we saw 
that the eosinophils from transplanted patients also reacted differently to systemic 
glucocorticoid treatment it was only the eosinophils from the patients with GVHD 
that altered their phenotype, which we take to indicate that it was only the activated 
eosinophils in GVHD that responsed, whereas the non-activated, resting 
eosinophils in the circulation of patients with other causes were not influenced by 
the steroids. We did not study patients with glucocorticoid-resistant GVHD. 
However, it would be interesting in further studies to see if the eosinophils express 
different surface markers in patients without response to glucocorticoids. If the 
eosinophils have different patterns of surface receptors also in these patients, it 
could shed light on the mechanisms underlying glucocorticoid-resistant GVHD, 
which is a disease with still a high mortality and morbidity.
196
 
In study 2 we examined the functional properties of the eosinophils. This is an area 
not much studied. Here we could see a significant inhibition of allogeneic T cell 
proliferation in our in vitro-model of GVHD. Interestingly, this effect was 
restricted to eosinophils and did not include the granulocyte suspension (most 
consisting of neutrophils). This control was done to exclude the possibility that it 
was merely a lack of nutrients that accounted for the reduced proliferation in 
eosinophil: PBMC co-cultures due to overcrowding. Nevertheless, other studies 
have reported the existence of particular neutrophil subsets with ability to inhibit 
T-cell proliferation.
197
 
We attempted to identify the T cell suppressive mechanism used by eosinophils 
and found that cell-cell contact was required. This does not preclude the 
involvement of soluble suppressive molecules, as it may be necessary to reach high 
local concentrations for such putative molecules to be suppressive. Earlier studies 
from the 80:s
126
, have shown that purified granule proteins ECP and EPX could 
inhibit lymphocyte proliferation. However, when we used whole eosinophils we 
could not abrogate their T cell suppressive capacity by administration of antibodies 
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to these granule proteins. Nor could we verify the neutralizing capacity of the 
selected antibodies as we were unable to reproduce the T cell suppressive capacity 
of purified granule proteins. As galectin-10 has been proposed to be responsible for 
the immunosuppressive function of Tregs
142
 we examined its expression in blood 
eosinophils from transplanted patients by help of RT-PCR. Interestingly, we found 
that galectin-10 mRNA increased in eosinophils from patients after allogeneic 
HSCT, compared to in healthy controls. However, we could not detect any 
differences in galectin-10 mRNA between patients with and without chronic 
GVHD. Other studies have documented elevations of galectin-10 in other diseases 
like in eosinophilic esophagitis,
105
 celiac disease
198
 and in asthmatic airway 
inflammation.
199,200
 Our result showing elevated galectin-10 mRNA levels in 
transplanted patients suggests that galectin-10 is required for some reason, possibly 
to help regulate a very dysregulated immune system as seen in the post-transplant 
setting. However, we could not clearly document that blockade of galectin-10 
abrogated the inhibitory capacity of eosinophils. 
However, additional later analyses in a thesis done by a member of our group  
indicated that part of the eosinophil-mediated suppression of allogeneic T cell  
proliferation could partly be restored (31%) by blocking galectin-10 using a larger 
number of study subjects and matched statistical analyses.
201
 Our conclusion is that  
galectin-10 may mediate part of the T cell suppression exerted by human 
eosinophils. Interestingly the inhibiting effect of the eosinophils on allogeneic T 
cell proliferation was seen also in eosinophils from transplanted patients, indicating 
that eosinophils in transplanted patients have preserved T cell suppressive capacity, 
at least in vitro. However, there were no differences in suppression between 
patients with chronic GVHD and not. One reason could be our small sample size. 
Another reason could be that our in vitro-model was not too robust and therefore 
did not have enough sensibility for this kind of experiments. These experiments  
are also technically advanced as the eosinophils can degranulate if they experience 
temperature differences. Another explanation could be that the eosinophil uses 
several mechanisms when inhibiting T cells, including both cell-cell contact and 
inhibition by help of soluble factors. If that is the case, it would be in common with 
other immunomodulatory cell types like human mesenchymal stromal cells, which 
use multiple mechanisms like IDO
202
 galectin-1
203
 and both soluble factors and 
cell-cell contact.
204
 
A challenge when studying allogeneic transplanted patients and especially GVHD 
is the large amount of possible confounding factors, which are known to influence 
the immune cells. The most evident are: different diseases before transplantation, 
different conditioning protocols and different post-transplantation complications 
like graft rejection, graft failure, relapse and therefore different 
immunosuppression. Another possible confounder when studying blood 
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eosinophils is that systemic glucocorticoids are known to decrease eosinophilic 
counts
205
 due to apoptosis of eosinophils.
206, 207
 As we were aware of this effect, we 
excluded patients with GVHD under systemic glucocorticoids in this MLR study. 
Therefore, we could unfortunately not include patients with severe GVHD, as they 
are under systemic treatment, but the advantage was that we could exclude this 
possible confounder. However, there is a need of studies of steroid resistant 
GVHD. As the blood eosinophil is rare in steroid-treated patient, we think it is 
important to include tissue samples and examine the role of the eosinophil as a 
tissue cell in future studies of GVHD and especially when studying steroid 
resistant GVHD. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.. Our model of the eosinophilic granulocyte in GVHD. The first reaction is increased 
eosinophil counts in acute GVHD. During GVHD, the eosinophil gets an activated phenotype 
with up-regulation of CD69, CD11c, CD9 and CD18 in the blood vessel. By help of these 
activation receptors, it can bind to the receptors ICAM-1 and VCAM-1 on the activated 
endothelium. In the tissues, the eosinophils can inhibit allogeneic T cell proliferation in acute 
and chronic GVHD by help of cell-cell contact and unknown soluble factors. The cells are 
reproduced with permission from DocCheck pictures.  
After these functional studies, we did a clinical study of GVHD after solid organ 
transplantations. This is a unique cohort as Sahlgrenska Transplant Institute was 
the only institute among the Scandinavian countries to perform this type of 
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transplants during the study period. A unique feature of this study population is 
that many patients with malignant diseases like pancreatic tumors with 
unresectable liver metastases were included. The most important finding was that 
patients transplanted because of a malignant disease had an increased risk of acute 
GVHD. Neoadjuvant chemotherapy was also a risk factor. To our knowledge, this 
has not been examined in other studies. Our interpretation is that the chemotherapy 
may have damaged the intestinal mucosa before transplantation. This resembles the 
situation before an allogeneic HSCT, in which the conditioning therapy damages 
organs with rapidly proliferating cells such as the GI tract, believed to be an 
essential first step in the development of acute GVHD. It likely that there is an 
increased permeability in the transplanted intestine and viscera, making it possible 
for bacterial products to enter the bloodstream and induce T cell activation. As a 
routine at our transplant center, the intestine is also placed as a stoma in the newly 
transplanted individual. This procedure facilitates examinations of the intestine, but 
also facilitates for bacterial products or contaminants to enter the bloodstream. 
It has been debated whether a spleen-containing graft and a recipient splenectomy 
could be a risk factor for acute GVHD in organ transplanted patients. One 
American studies indicates that a spleen containing graft could be a risk factor.
20
 
Others have not found that spleen-containing grafts are associated with an 
increased risk of GVHD.
208-210
 The spleen is a lymphatic organ and the hypothesis 
is that the transferred lymphocytes will react to foreign tissue antigens in the donor 
(who is under immunosuppression). However, we could not find an increased 
incidence of GVHD among the patients with a spleen-containing graft. This may 
be a false negative result due to our modest number of patients.  
None of our patients incurred chronic GVHD. This is in agreement with studies 
from other groups.
20, 211
 It is unclear why chronic GVHD is less common after ITX 
or MVTX than after allogeneic HSCT. A likely explanation is that the solid organ 
transplanted patients maintain their own immune system, and are less 
immunologically deranged compared to the HSCT transplanted patient. 
Fortunately, all of our patients survived their episodes of acute GVHD. Due to the 
small sample size, it is difficult to make analyses of the underlying causes. 
However, one possible explanation could perhaps be that we used a quite generous 
definition of GVHD, as clinical features compatible with GVHD and a positive 
DNA chimerism analysis was enough to define GVHD. Therefore, it is likely that 
patients with a less severe acute GVHD were included, compared to if we would 
have included only those with a positive biopsy.  
Chimerism analyses are used to facilitate the diagnosis of GVHD after solid organ 
transplantation. However, in our study of patients after MVTX, one patient had 
macrochimerism (27% donor T cells) without signs of acute GVHD. This is in 
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congruence with another study
75
 which also reports macrochimerism without 
GVHD after ITX or MVTX. In addition, GVHD can also occur without detectable 
donor lymphocytes in blood.
212
 This reflects the difficulties to diagnose GVHD 
after ITX or MVTX. Our interpretation is that macrochimerism has to be 
interpreted in combination with clinical features. At the moment, routine 
chimerism analyses are not done after solid organ transplantation at our transplant 
center. However, as also the histopathological diagnosis of skin GVHD is difficult, 
we think it would be valuable to do more regular chimerism analyses after ITX or 
MVTX, to follow trends and thereby facilitate the diagnosis and regulation of 
immunosuppression.  
After these chimerism studies in GVHD following MVTX, we continued to focus 
on chimerism analyses after HSCT. In this setting, chimerism analyses are done 
routinely. The difference here is that it is desirable for the patient to achieve 
complete chimerism status with 100% donor T cells as opposed to mixed 
chimerism. This is a difference compared to after solid-organ transplantation when 
the recipient is supposed to maintain their own immune system and their recipient 
T cells.  
In study IV we analyzed whether T-cell chimerism status on 100 days after 
allogeneic RICT could predict overall survival, relapse incidence, disease-free 
survival, non-relapse mortality and GVHD. In this retrospective study, we could 
not see an association between chimerism status and these patient-related 
outcomes. This is in contrast to some other studies, which have documented a 
shorter overall survival in patients with mixed chimerism on day 30 or day 100. 
213, 
214
. A recent study also found that mixed chimerism with recipient cells among the 
CD34
+
 and CD8
+
 cell subsets after a period of complete chimerism, predicted an 
increased risk of relapse in patients with acute lymphoblastic leukemia.
215
 Other 
studies have shown increased risk of relapse after MAC conditioning.
216-218
 
However, there is also a study of MAC treated patients showing a connection with 
rejection instead of relapse.
219
 Another study  of RICT treated patients indicates 
that mixed chimerism can be associated with relapse.
220
 
The reason why we could not see shorter survival in our studies of chimerism 
could be that all our patients were treated with RICT. It is more prevalent with 
mixed chimerism after RICT, than after MAC
221
, and we suppose that mixed 
chimerism after MAC therefore is a more sensitive test for prediction of rejection 
and relapse. Another difference in our study was that we did not analyze cell 
subsets and that we used a cut-off level for mixed chimerism of >4% recipient T 
cells, which is higher than in some of the other studies. In a Chinese study, they 
used a lower cut-off level of >1% recipient T cells.
222
 Concerning relapse incidence 
and non-relapse mortality, we only had 25 relapses among the patients, and 
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therefore the study probably is under-powered to answer the question about 
relapses. Our modest number of relapses is because patients with a verified relapse 
before day 100 were excluded.  
In study IV, we only included one chimerism value on 100 days. It is possible that 
another study design with inclusion of several chimerism samples and analysis of 
“trends” of chimerism towards more complete or mixed chimerism, would have 
shown more results. This type of study design would be easier to perform in a 
prospective study design, as chimerism samples then could be done both on regular 
interval and on demand after suspected signs of GVHD. Another advantage with a 
prospective study design is that the diagnosis of GVHD would be more assured, 
when it is reported instantly. In retrospective studies, it is difficult to interpret 
clinical signs of GVHD via medical records several years afterwards.  
An unexpected finding was that patients with mixed chimerism had longer 
treatment time with CsA. We had expected that many clinicians would interpret 
mixed chimerism as sign of threatening relapse and taper CsA more rapidly. A 
probable explanation can be that CsA initially was tapered faster in patients with 
mixed chimerism and they therefore achieved signs of chronic GVHD. Then the 
chronic GVHD implicated a prolonged CsA treatment, Another reason could be 
that several patients with mixed chimerism received donor lymphocyte infusions 
(DLI:s), which is a known risk factor for acute and chronic GVHD.
223,224
 
Alternatively, the prolonged CsA treatment induced chronic GVHD as CsA can 
induce a GVHD-like reaction after autologous or syngeneic HSCT.
225
. Experiments 
in mice have shown that CsA can induce chronic GVHD by an inhibited 
reconstitution of bone marrow derived Tregs.
226
 The patients with grafts from 
related donor had significantly more chronic GVHD. One possible explanation is 
the use of ATG after grafts from unrelated donor at our hospital. A recent 
randomized multicenter study showed a significant reduction of chronic GVHD 
two years after transplantation with ATG.
227
  
Unfortunately, we could not find any association between neither classical acute 
GVHD nor chronic GVHD and chimerism status. Several other studies have shown 
an association between complete chimerism on day 90
228
 and GVHD. Sometimes 
mixed chimerism on day 30
229-231
 is thought to “protect” against GVHD. One 
reason for why we could not find an association between complete chimerism  and 
acute GVHD is that it was not always clear if the patients had contracted acute 
GVHD in retrospect. To be sure that we only included certain cases of acute 
GVHD, we only included the cases with a verified biopsy. It is therefore a 
possibility that we missed some cases. Concerning chronic GVHD, the statistical 
analysis was insufficient as we did not find the debut date of chronic GVHD. 
Therefore, we only could do logistic regression instead of Kaplan-Meier tests.  
56 
 
In conclusion, chimerism status on day 100 could not be used to predict GVHD, 
overall survival or relapse in our population of patients with malignant 
hematological diagnoses after RICT. Prospective studies of selected patients and 
more frequent chimerism sampling of cell subsets would probably clarify the 
possible utility of chimerism analyses.  
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The eosinophilic granulocytes have activated surface receptors in peripheral blood 
from patients with  acute and chronic GVHD. Our hypothesis is that these 
receptors facilitate the binding of the eosinophils to the vascular endothelium and 
their further migration into the affected tissues. The first-line treatment of GVHD 
is glucocorticoids. Start of treatment with systemic glucocorticoids decreases the 
numbers of eosinophils in blood and down-regulate their surface receptors.  
Functional studies of the eosinophils also show that it can be immunosuppressive 
and inhibit allogeneic T cell proliferation in vitro. This effect is dependent of cell-
cell contact between T cells and eosinophils.  
Patients with a tumor diagnosis or neoadjuvant chemotherapy or radiotherapy are 
at an increased risk of GVHD after a multivisceral transplantation. Among 26 
patients, (5/26) 19% incurred acute GVHD and the mortality was lower than 
expected as all survived their episode of acute GVHD.  
Chimerism status on day 100 after allogeneic HSCT cannot be used to predict 
overall survival, GVHD status or relapse incidence. Patients with mixed chimerism 
and chronic GVHD have prolonged treatment with cyclosporine A, (CsA). It is 
probable that the CsA initially was tapered faster in patients with mixed 
chimerism. Therefore, they were at higher risk of incurring chronic GVHD and 
signs of chronic GVHD implicated a prolonged treatment of CsA. Other 
explanations could be that patients with mixed chimerism more often are treated 
with donor lymphocyte infusions, which is a risk factor of GVHD or that the CsA 
in itself elevates the risk of incurring chronic GVHD.  
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My ideas of futures project in the field of preventing, diagnosing and treating 
GVHD after allogeneic hematopoietic stem cell transplantation and multivisceral 
transplantation: 
 Improve functional studies of the inhibiting effect of the 
eosinophil on T cells  
Do more anti-inhibiting studies to identify one or several inhibiting mechanisms 
together. An evaluation of whether the inhibition effect is done by help of 
apoptosis or necrosis. 
 Better prevention of GVHD 
Identification of high-risk individuals to make a more individual treatment. 
Prospective large cohort studies to identify possible risk factors for GVHD.  
 Improved diagnostics of GVHD 
Prospective studies to follow immune status and chimerism status directly in the 
post-transplant period after HSCT and MVTX. For example examination of blood 
????????????????????????????????????????????????????????????????????????????????????
of GVHD, to better understand the post-transplant microenvironment. 
As GVHD is a relatively new and rare disease, it is very important with 
international collaboration concerning diagnosis, treatment and nomenclature. Here 
multi-center studies will be needed to succeed with these questions. 
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